[{"Abstract":"Background: Immune checkpoint inhibitors (ICIs) have recently improved the prognosis of various cancers. In contrast, some immune-related adverse events (irAEs) caused by ICIs are fatal and have become problematic. The pathogenesis of irAEs remains unknown and must be elucidated to establish biomarkers.<br \/>Materials and Methods: Plasma samples were collected prospectively from patients with advanced and metastatic renal cell carcinoma (RCC) prior to initiation of ICI treatment (baseline) and 2 or 3 weeks after the first cycle of ICI treatment (post-dose 1). Plasma cytokines and chemokines (GRO [CXCL1], IL-17A, IL-1&#946;, IL-6, IL-8, IP-10 [CXCL10], MCP-1 [CCL2], TNF&#945;) were measured by Luminex system, and plasma level of CXCL13 and anti-CD74 autoantibody levels were measured by ELISA. Their association with irAEs was analyzed.<br \/>Results: In a discovery cohort of 13 patients, plasma levels of CXCL1, IL-17A, IL-1&#946;, IL-6, IL-8, CXCL10, MCP-1, and TNF&#945; were measured at baseline and post-dose 1. Only CXCL10, at post-dose 1 but not at baseline, was significantly associated with grade 2 or higher irAEs (<i>p<\/i>=0.0413). Plasma CXCL10 levels were then measured at baseline and post-dose 1 in a validation cohort of 43 RCC patients who received ICI-based treatment. Higher plasma CXCL10 levels both at baseline and post-dose1 were significantly associated with the occurrence of grade 2 or higher irAEs (<i>p<\/i>=0.0246 and 0.0137, respectively). We evaluated the relationship between plasma levels of CXCL10 and CXCL13, which we measured in a previous study, and the incidence of irAEs. At baseline, the plasma CXCL13 level was positively associated with the CXCL10 level (<i>p<\/i>=0.0007), but no significant association was observed post-dose 1 (<i>p<\/i>=0.2678). Plasma CXCL13 levels were significantly higher in patients with grade 2 or higher irAEs at baseline but not at post-dose 1 (<i>p<\/i>=0.0037 and 0.052, respectively). No significant association between plasma anti-CD74 autoantibody level and both irAE pneumonitis and any grade 2 or higher irAE was observed.<br \/>Conclusion: Plasma CXCL10 is significantly associated with the occurrence of irAEs in patients with RCC treated with ICIs. CXCL10 is a potential predictive and on-treatment biomarker for irAEs.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Chemokines,Immune checkpoint blockade,Kidney cancer,Toxicity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Yuji Miura<\/b><sup>1<\/sup>, Takanobu Motoshima<sup>2<\/sup>, Toshiki Anami<sup>2<\/sup>, Hiromu Yano<sup>1<\/sup>, Remi Mito<sup>1<\/sup>, Shinji Urakami<sup>3<\/sup>, Keiichi Kinowaki<sup>4<\/sup>, Hirotake Tsukamoto<sup>5<\/sup>, Ryoma Kurahashi<sup>2<\/sup>, Yoji Murakami<sup>2<\/sup>, Junji Yatsuda<sup>2<\/sup>, Yukio Fujiwara<sup>1<\/sup>, Tomomi Kamba<sup>2<\/sup>, Yoshihiro Komohara<sup>1<\/sup><br><br\/><sup>1<\/sup>Cell Pathology, Kumamoto Univ Graduate School of Medical Sci, Kumamoto, Japan,<sup>2<\/sup>Urology, Kumamoto Univ Graduate School of Medical Sci, Kumamoto, Japan,<sup>3<\/sup>Urology, Toranomon Hospital, Tokyo, Japan,<sup>4<\/sup>Pathology, Toranomon Hospital, Tokyo, Japan,<sup>5<\/sup>Clinical Immunology and Cancer Immunotherapy, Kyoto University, Kyoto, Japan","CSlideId":"","ControlKey":"dab9845a-facb-49ff-8360-12a1e4bb2594","ControlNumber":"1906","DisclosureBlock":"<b>&nbsp;Y. Miura, <\/b> <br><b>ONO Pharmaceutical<\/b> Other, Honoraria. <br><b>Bristol-Myers Squibb<\/b> Other, Honoraria. <br><b>MSD<\/b> Other, Honoraria. <br><b>Eisai<\/b> Other, Honoraria. <br><b>Takeda<\/b> Other, Honoraria.<br><b>T. Motoshima, <\/b> None..<br><b>T. Anami, <\/b> None..<br><b>H. Yano, <\/b> None..<br><b>R. Mito, <\/b> None..<br><b>S. Urakami, <\/b> None..<br><b>K. Kinowaki, <\/b> None..<br><b>H. Tsukamoto, <\/b> None..<br><b>R. Kurahashi, <\/b> None..<br><b>Y. Murakami, <\/b> None..<br><b>J. Yatsuda, <\/b> None..<br><b>Y. Fujiwara, <\/b> None.&nbsp;<br><b>T. Kamba, <\/b> <br><b>Merck Biopharma<\/b> Other, Honoraria.<br><b>Y. Komohara, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4133","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4326","PresenterBiography":null,"PresenterDisplayName":"Yuji Miura, MD","PresenterKey":"c79465ed-2894-4705-84a8-ddafb1204d77","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4326. Predictive value of CXCL10 for the occurrence of immune related adverse events in patient with renal cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Predictive value of CXCL10 for the occurrence of immune related adverse events in patient with renal cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Microsatellite instability (MSI) is caused by deficient DNA mismatch repair (MMR) and is a ubiquitous feature of cancer. Werner syndrome (WRN) helicase is involved in genome stability and DNA repair. We identified WRN as a synthetic-lethal target in dMMR\/MSI cancers and highlighted WRN inhibition as a therapeutic option for dMMR\/MSI cancers refractory to available therapies. A previously unappreciated genetic feature of dMMR\/MSI cancer cells, DNA (TA)n-dinucleotide repeat expansions, were recently reported to cause vulnerability to WRN depletion. Our mechanistic understanding of TA-dinucleotide repeat expansion biology is limited, and their potential therapeutic implications are unclear. To investigate the landscape of these alterations in cancer, we inferred (TA)-dinucleotide repeat expansions by performing coverage analysis in a collection of hundreds of preclinical cancer models and human tumors (PCAWG) profiled by whole genome sequencing (WGS). We validated our findings in cancer cell lines and organoid cultures by performing long-read WGS. Furthermore, we investigated TA-expansions in single-cell-derived clones from human MSI tumors and cancer organoids. Finally, we inferred TA repeats in laser capture microdissection (LCMB)-derived samples obtained from patients affected by familial cancer predisposition syndromes. Our analysis unveils the landscape of TA-repeats alterations in a large collection of tumors and preclinical models, informing on the level of inter-tumor heterogeneity and their association with variable levels of WRN dependency. In addition, we investigated intra-patient tumor heterogeneity of TA-repeats length both within clonal organoids expanded from normal and neoplastic colorectal stem cells, and within different subclones derived from MSI cancer organoids. Furthermore, analysis of non-neoplastic and neoplastic tissues from patients affected by familial cancer predisposition syndromes revealed the pattern of TA-repeats expansions associated with various DNA-repair pathway alterations. Finally, we will discuss the clinical implications of our findings, as TA-repeats heterogeneity may affect sensitivity and resistance to the future generation of WRN inhibitors. Our data provide fresh insights into the inter and intra-tumoral heterogeneity of TA-dinucleotide repeat expansions in human cancers. These data contribute to understanding the role of MMR in cancer and exploiting Werner as a therapeutic target in cancer.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Mismatch repair deficiency,DNA repair,Synthetic lethality,Therapeutic target,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Gabriele Picco<\/b><sup>1<\/sup>, Shriram Bhosle<sup>1<\/sup>, Maria Kalyva<sup>2<\/sup>, Elena Grassi<sup>3<\/sup>, Freddy Gibson<sup>1<\/sup>, Angham Al Saedi<sup>1<\/sup>, Sara Vieira<sup>1<\/sup>, Mathijs Sanders<sup>4<\/sup>, Livio Trusolino<sup>5<\/sup>, Andrea Bertotti<sup>5<\/sup>, Isidro Cortes-Ciriano<sup>6<\/sup>, Mathew Garnett<sup>1<\/sup><br><br\/><sup>1<\/sup>Wellcome Sanger Institute, Hinxton, United Kingdom,<sup>2<\/sup>European Molecular Biology Laboratory- European Bioinformatics Institute EMBL-EBI, Hinxton, United Kingdom,<sup>3<\/sup>Candiolo Cancer Institute, Translational Cancer Medicine, Candiolo, Italy,<sup>4<\/sup>Erasmus University Medical Center, Rotterdam, Netherlands,<sup>5<\/sup>Candiolo Cancer Institute, Candiolo, Italy,<sup>6<\/sup>European Molecular Biology Laboratory, Hinxton, United Kingdom","CSlideId":"","ControlKey":"fcc65998-cff4-4c0b-9174-1ec0cef4bf34","ControlNumber":"5905","DisclosureBlock":"<b>&nbsp;G. Picco, <\/b> <br><b>GSK<\/b> Other, Research grant.<br><b>S. Bhosle, <\/b> None..<br><b>M. Kalyva, <\/b> None..<br><b>E. Grassi, <\/b> None..<br><b>F. Gibson, <\/b> None..<br><b>A. Al Saedi, <\/b> None..<br><b>S. Vieira, <\/b> None..<br><b>M. Sanders, <\/b> None..<br><b>L. Trusolino, <\/b> None..<br><b>A. Bertotti, <\/b> None..<br><b>I. Cortes-Ciriano, <\/b> None..<br><b>M. Garnett, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4134","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4327","PresenterBiography":null,"PresenterDisplayName":"Gabriele Picco","PresenterKey":"01f337ad-a062-40b7-a167-bacd95ca44d6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4327. MSI cancer associated DNA (TA)n-dinucleotide repeat expansions and implications for Werner synthetic lethality","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"MSI cancer associated DNA (TA)n-dinucleotide repeat expansions and implications for Werner synthetic lethality","Topics":null,"cSlideId":""},{"Abstract":"Background: Immune-checkpoint inhibitors (ICIs) have improved the clinical benefit of only a subset of patients with advanced non-small cell lung cancer (NSCLC), since tissue PD-L1 has showed low predictive accuracy. We have previously showed that extracellular vesicle (EV) PD-L1 identified durable responders to ICIs and that the radiomics analysis of baseline CT scans improved the EV PD-L1 predictive model. Here, we aim to validate this combination model to identify non-responders to ICIs.<br \/>Methods: We enrolled 3 cohorts of patients, cohort (1) included 27 patients receiving ICIs, cohort (2) 17 on ICIs + chemotherapy (ChT), and cohort (3) with 13 undergoing ChT. Baseline and 3<sup>rd<\/sup> cycle plasma samples were collected, EV were isolated by ultracentrifugation, and EV PD-L1 dynamics was analyzed by immunoblot. 800 radiomics features were evaluated in baseline CT scans and a set of 6 features identified in cohort 1, were analyzed in cohort 2 and 3. Early and durable responses were assessed in CT scans after the 3<sup>rd<\/sup> and the 6-8 treatment cycle, respectively, using RECIST v1.1.<br \/>Results: Increased expression of EV PD-L1 during treatment showed good predictive value at identify non-responders to ICIs and was not associated with ChT response. The addition of radiomics features improved the predictive model for early and durable response to ICIs, while similar AUC was observed in particular for durable response in cohort 2. Moreover, these biomarkers outperformed tissue PD-L1 and were unspecific for response to Docetaxel (Table 1). No predictive models could be evaluated for early response to ChT.<br \/>Conclusions: We present for the first time, validated evidence of the combination of EV PD-L1 and radiomics as a highly accurate minimally invasive biomarker for predicting response to ICIs. This combinatorial approach outperformed the current standard-of-care tissue PD-L1 and is a promising tool for the stratification of patients to receive ICIs.<br \/><table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{21BFF9FB-32C2-4850-B417-F160BD605FC2}\"><caption>Table 1: Predictive models for early and durable response:<\/caption><tr><td rowspan=\"1\" colspan=\"10\"><b>A: Predictive models for early RECIST response (3 treatment cycles)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Cohort:<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>1: ICIs (n=27)<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>2: ICIs + Docetaxel (n=17)<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>3: Docetaxel (n=13)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Biomarker:<\/b><\/td><td rowspan=\"1\" colspan=\"1\">AUC<\/td><td rowspan=\"1\" colspan=\"1\">Sensitivity<\/td><td rowspan=\"1\" colspan=\"1\">Specificity<\/td><td rowspan=\"1\" colspan=\"1\">AUC<\/td><td rowspan=\"1\" colspan=\"1\">Sensitivity<\/td><td rowspan=\"1\" colspan=\"1\">Specificity<\/td><td rowspan=\"1\" colspan=\"1\">AUC<\/td><td rowspan=\"1\" colspan=\"1\">Sensitivity<\/td><td rowspan=\"1\" colspan=\"1\">Specificity<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>&#916;EV PD-L1 + Radiomics<\/b><\/td><td rowspan=\"1\" colspan=\"1\">73.3%<\/td><td rowspan=\"1\" colspan=\"1\">83.3%<\/td><td rowspan=\"1\" colspan=\"1\">73.3%<\/td><td rowspan=\"1\" colspan=\"1\">75.0%<\/td><td rowspan=\"1\" colspan=\"1\">100.0%<\/td><td rowspan=\"1\" colspan=\"1\">75.0%<\/td><td rowspan=\"1\" colspan=\"3\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>&#916;EV PD-L1<\/b><\/td><td rowspan=\"1\" colspan=\"1\">61.7%<\/td><td rowspan=\"1\" colspan=\"1\">50.0%<\/td><td rowspan=\"1\" colspan=\"1\">73.3%<\/td><td rowspan=\"1\" colspan=\"1\">71.9%<\/td><td rowspan=\"1\" colspan=\"1\">100.0%<\/td><td rowspan=\"1\" colspan=\"1\">56.3%<\/td><td rowspan=\"1\" colspan=\"3\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Radiomics<\/b><\/td><td rowspan=\"1\" colspan=\"1\">67.8%<\/td><td rowspan=\"1\" colspan=\"1\">83.3%<\/td><td rowspan=\"1\" colspan=\"1\">53.3%<\/td><td rowspan=\"1\" colspan=\"1\">90.6%<\/td><td rowspan=\"1\" colspan=\"1\">100.0%<\/td><td rowspan=\"1\" colspan=\"1\">87.5%<\/td><td rowspan=\"1\" colspan=\"3\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Tissue PD-L1 &#8805;1%<\/b><\/td><td rowspan=\"1\" colspan=\"1\">57.5%<\/td><td rowspan=\"1\" colspan=\"1\">75.0%<\/td><td rowspan=\"1\" colspan=\"1\">40.0%<\/td><td rowspan=\"1\" colspan=\"1\">62.5%<\/td><td rowspan=\"1\" colspan=\"1\">100.0%<\/td><td rowspan=\"1\" colspan=\"1\">25.0%<\/td><td rowspan=\"1\" colspan=\"3\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"10\"><b>B: Predictive models for durable RECIST response (6-8 treatment cycles)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Cohort:<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>1: ICIs (n=27)<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>2: ICIs + Docetaxel (n=17)<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>3: Docetaxel (n=13)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Biomarker:<\/b><\/td><td rowspan=\"1\" colspan=\"1\">AUC<\/td><td rowspan=\"1\" colspan=\"1\">Sensitivity<\/td><td rowspan=\"1\" colspan=\"1\">Specificity<\/td><td rowspan=\"1\" colspan=\"1\">AUC<\/td><td rowspan=\"1\" colspan=\"1\">Sensitivity<\/td><td rowspan=\"1\" colspan=\"1\">Specificity<\/td><td rowspan=\"1\" colspan=\"1\">AUC<\/td><td rowspan=\"1\" colspan=\"1\">Sensitivity<\/td><td rowspan=\"1\" colspan=\"1\">Specificity<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>&#916;EV PD-L1 + Radiomics<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">81.3%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">75.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">90.9%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">76.7%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">100.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">66.7%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">53.6%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">42.9%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">83.3%<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>&#916;EV PD-L1<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">72.7%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">56.3%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">81.8%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">83.3%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">50.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">100.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">54.8%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">28.6%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">83.3%<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Radiomics<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">71.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">50.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">90.9%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">61.7%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">50.0%<\/span><br><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">80.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">57.1%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">42.9%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">83.3%<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Tissue PD-L1 &#8805;1%<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">60.2%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">75.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">54.5%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">63.3%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">100.0%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">26.7%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">52.4%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">28.6%<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span lang=\"EN-US\" style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">66.6%<\/span><\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Extracellular vesicles,Radiomics,Immune checkpoint blockade,Lung cancer: non-small cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Murat Ak<\/b><sup>1<\/sup>, Diego De Miguel Perez<sup>2<\/sup>, Priyadarshini Mamindla<sup>1<\/sup>, Alessandro Russo<sup>3<\/sup>, Vishal Peddagangireddy<sup>1<\/sup>, Mehmet  E.  Er<sup>1<\/sup>, &#350;erafettin Zenkin<sup>1<\/sup>, Muthukumar Gunasekaran<sup>4<\/sup>, Luis Lara-Mejia<sup>5<\/sup>, Francesco Buemi<sup>3<\/sup>, Feliciano Barron<sup>5<\/sup>, Marisol Arroyo-Hernández<sup>5<\/sup>, Sunjay Kaushal<sup>4<\/sup>, Andres  F.  Cardona<sup>6<\/sup>, Aung Naing<sup>7<\/sup>, Vincenzo Adamo<sup>3<\/sup>, Oscar Arrieta<sup>5<\/sup>, Rivka  R.  Colen<sup>1<\/sup>, Christian Rolfo<sup>2<\/sup><br><br\/><sup>1<\/sup>Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA,<sup>2<\/sup>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY,<sup>3<\/sup>Medical Oncology Unit, A.O. Papardo & Department of Human Pathology, University of Messina, Messina, Italy,<sup>4<\/sup>Departments of Surgery and Pediatrics, Ann and Robert H. Lurie Children’s Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, IL,<sup>5<\/sup>Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico,<sup>6<\/sup>Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Universidad El Bosque, Bogota, Colombia,<sup>7<\/sup>Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"acf109ad-38b7-45c3-ad0e-30cebfc0cfb0","ControlNumber":"3836","DisclosureBlock":"&nbsp;<b>M. Ak, <\/b> None..<br><b>D. De Miguel Perez, <\/b> None..<br><b>P. Mamindla, <\/b> None.&nbsp;<br><b>A. Russo, <\/b> <br><b>AstraZeneca<\/b> Advisory role\/ Consultancy. <br><b>Novartis<\/b> Advisory role\/ Consultancy. <br><b>MSD<\/b> Advisory role\/ Consultancy.<br><b>V. Peddagangireddy, <\/b> None..<br><b>M. E. Er, <\/b> None..<br><b>&. Zenkin, <\/b> None..<br><b>M. Gunasekaran, <\/b> None..<br><b>L. Lara-Mejia, <\/b> None..<br><b>F. Buemi, <\/b> None..<br><b>F. Barron, <\/b> None..<br><b>M. Arroyo-Hernández, <\/b> None..<br><b>S. Kaushal, <\/b> None.&nbsp;<br><b>A. F. Cardona, <\/b> <br><b>Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Thermo Fisher, Broad Institute, BioNTech, Amgen, Flatiron Health, Teva Pharma, Rochem B<\/b> Other, Research support. <br><b>EISAI, Merck Serono, Jannsen Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant<\/b> Advisory role. <br><b>A. Naing, <\/b> <br><b>NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor\/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX<\/b> Other, Research funding. <br><b>CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, Kymab, STCube Pharmaceuticals, Deka Biosciences,  Takeda, CSL, Behring, Horizon, and Pharming.<\/b> Other, Advisory board role. <br><b>ARMO BioSciences<\/b> Travel. <br><b>Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta<\/b> Other, Spouse and research funding.<br><b>V. Adamo, <\/b> None..<br><b>O. Arrieta, <\/b> None..<br><b>R. R. Colen, <\/b> None.&nbsp;<br><b>C. Rolfo, <\/b> <br><b>EMD Serono<\/b> Other, Consulting\/advisory board\u000d\u000aSafety Monitoring Board. <br><b>AstraZeneca<\/b> Other, Speaker. <br><b>Roche<\/b> Other, Speaker. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Mirati<\/b> Other, Consulting\/advisory board. <br><b>Eisai<\/b> Consulting\/advisory board. <br><b>COR2ED<\/b> Speaker. <br><b>Daiichi Sankyo<\/b> Other, Consulting\/advisory board. <br><b>Sanofi Genzyme- Regeneron<\/b> Other, Consulting\/advisory board. <br><b>Physicians Education Resource, LLC.<\/b> Other, Speaker. <br><b>Intellisphere, LLC<\/b> Other, Speaker. <br><b>CEA<\/b> Other, Speaker\u000d\u000aConsulting\/advisory board. <br><b>Bayer U.C. LLC<\/b> Other, Consulting\/advisory board. <br><b>General Dynamics<\/b> Other, Consulting\/advisory board. <br><b>Janssen Scientific Affairs<\/b> Other, Consulting\/advisory board. <br><b>ISLB, IASLC, ESO, ESMO, Elsevier<\/b> Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4136","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4329","PresenterBiography":null,"PresenterDisplayName":"Murat Ak, MD","PresenterKey":"e041d002-fb6e-451d-84ee-4c9adfb873fb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4329. Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Gene expression profiling has identified DLBCLs that bear transcriptional similarity to either non-malignant germinal center B-cells (GCB-DLBCL) or activated B-cells (ABC-DLBCL, i.e. non-GCB-DLBCL). This cell-of-origin (COO) classification has guided precision medicine strategies, including the use of ibrutinib, a BTK inhibitor (BTKi), with ABC-DLBCLs thought to be sensitive to BTKi due to their constitutive activation of NF-kB downstream of the B-cell receptor (BCR). However, the phase III Phoenix trial testing the addition of ibrutinib to R-CHOP chemoimmunotherapy surprisingly failed to demonstrate a survival benefit in non-GCB-DLBCLs. By employing a newly defined genetic classification algorithm (LymphGen), distinct genetic DLBCL subtypes that benefit from this regimen were identified. However, LymphGen is not utilized in the clinic and fails to classify &#62;40% of DLBCLs. To overcome these challenges, we sought to identify a straightforward biomarker of BTKi sensitivity. CD5 was selected as a potential candidate, given its role as a negative regulator of BCR signaling and expression in other BTKi-responsive B-cell lymphomas.<br \/>Methods: CD5 IHC was performed on a cohort of 405 DLBCLs, most with paired RNA and targeted mutational sequencing. Comparison of the transcriptomes of CD5<sup>+<\/sup> and CD5<sup>-<\/sup> DLBCLs was used to construct a 60-gene CD5 signature (CD5sig), which was applied to large genomic DLBCL datasets, including pre-treatment biopsies from the Phoenix trial (n = 584) to evaluate its utility in predicting improved response to R-CHOP + ibrutinib.<br \/>Results: Twenty-seven DLBCLs were identified as CD5<sup>+<\/sup> by IHC (6% of cases; 12% of non-GCB). Consistent with previous reports, CD5<sup>+<\/sup> DLBCLs were enriched for a non-GCB COO and exhibited inferior progression-free survival to R-CHOP. CD5<sup>+<\/sup> DLBCLs upregulated genes related to BCR signaling and had a significantly higher incidence of <i>CD79B <\/i>BCR-activating mutations. A CD5 signature (CD5sig) was created from differentially expressed genes between CD5 IHC<sup>+<\/sup> and CD5 IHC<sup>-<\/sup> non-GCB-DLBCLs. When applied to an external dataset of 349 non-GCB-DLBCLs, CD5sig<sup>+<\/sup> DLBCLs (15% of cases) were enriched for BCR-activating mutations and were majority MCD (<i>MYD88<\/i> and <i>CD79B<\/i>) or unclassified by LymphGen. CD5sig<sup>+<\/sup> DLBCLs were largely devoid of <i>BCL10<\/i> activating mutations known to drive BTKi resistance. When applied to the Phoenix study, CD5sig<sup>+<\/sup> DLBCLs selectively benefitted from R-CHOP + ibrutinib by event-free and overall survival. This survival difference was preserved even among LymphGen-unclassified DLBCLs.<br \/>Conclusions: Here, we identify CD5 expression as a simple and useful biomarker to identify high-risk, BCR-driven DLBCLs beyond those identified through genetic classification. Based upon unique transcriptional features of CD5 IHC<sup>+<\/sup> DLBCLs, we developed a novel CD5 signature that identifies DLBCLs vulnerable to BTKi therapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Diffuse large B-cell lymphoma,BTK,Precision medicine,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Alan Cooper<\/b><sup>1<\/sup>, Sravya Tumuluru<sup>1<\/sup>, Kyle Kissick<sup>2<\/sup>, Girish Venkataraman<sup>2<\/sup>, Nikita Kotlov<sup>3<\/sup>, Aleksander Bagaev<sup>3<\/sup>, Andrew Lytle<sup>4<\/sup>, Gerben Duns<sup>4<\/sup>, David  W.  Scott<sup>4<\/sup>, Christian Steidl<sup>4<\/sup>, Brendan Hodkinson<sup>5<\/sup>, Srimathi Srinivasan<sup>5<\/sup>, Justin Kline<sup>6<\/sup>, James Godfrey<sup>7<\/sup><br><br\/><sup>1<\/sup>University of Chicago, Chicago, IL,<sup>2<\/sup>Pathology, University of Chicago, Chicago, IL,<sup>3<\/sup>BostonGene, Waltham, MA,<sup>4<\/sup>Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada,<sup>5<\/sup>Janssen Research & Development, Spring House, PA,<sup>6<\/sup>Medicine, University of Chicago, Chicago, IL,<sup>7<\/sup>Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA","CSlideId":"","ControlKey":"17d146a8-8e7e-4ca6-aa1c-358e6c33b59a","ControlNumber":"1717","DisclosureBlock":"&nbsp;<b>A. Cooper, <\/b> None..<br><b>S. Tumuluru, <\/b> None..<br><b>K. Kissick, <\/b> None..<br><b>G. Venkataraman, <\/b> None..<br><b>N. Kotlov, <\/b> None..<br><b>A. Bagaev, <\/b> None..<br><b>A. Lytle, <\/b> None..<br><b>G. Duns, <\/b> None..<br><b>D. W. Scott, <\/b> None..<br><b>C. Steidl, <\/b> None.&nbsp;<br><b>B. Hodkinson, <\/b> <br><b>Janssen Research & Development<\/b> Employment. <br><b>S. Srinivasan, <\/b> <br><b>Janssen Research & Development<\/b> Employment.<br><b>J. Kline, <\/b> None..<br><b>J. Godfrey, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4137","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4330","PresenterBiography":null,"PresenterDisplayName":"Alan Cooper","PresenterKey":"bd525834-8bfe-4df2-886a-40262ba57941","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4330. A CD5 signature identifies diffuse large B-cell lymphomas (DLBCLs) sensitive to Bruton&#8217;s tyrosine kinase (BTK) inhibition","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A CD5 signature identifies diffuse large B-cell lymphomas (DLBCLs) sensitive to Bruton&#8217;s tyrosine kinase (BTK) inhibition","Topics":null,"cSlideId":""},{"Abstract":"Purpose: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) are the main drugs used to treat metastatic renal cell carcinoma (mRCC), but there are no effective biomarkers to determine their use. In this study, we aimed to identify factors that correlate with staging of RCC and drug sensitivity to mRCC based on the results of an in-house cancer gene panel test at Fujita Health University.<br \/>Methods: 133 patients with RCC (70 non-metastatic RCC and 63 mRCC). DNA was analyzed for mutations in 143 cancer genes using the PleSSision Rapid cancer gene panel test. NextSeq2000 was used as the next-generation sequencer. From the curated reports obtained, factors including each gene mutation information and the correlation between copy number (CN) variation (CNV) cluster analysis information, clinicopathological information, and therapeutic response to ICI or TKI was examined. In this study, the therapeutic response was evaluated with RECIST1.1 and complete response and partial response were determined as objective response (OR). The endpoint was progression-free survival 2 (PFS2) defined as the interval between first-line treatment and the second relapse.<br \/>Result: Mutational analysis showed no difference in the pattern of genetic variation with or without metastasis. CNV analyses showed a marked trend toward a decrease in CN on homologous recombination repair genes in a part of mRCCs. Cluster analysis of CNV information for each gene in response to TKI treatment in mRCC revealed multiple regions of decreased or increased CN. The main regions of increased CN were shown to be those formed by CN gain of oncogenes on chromosomes 7 and 12. Detailed analysis of this hot spot showed that when the cutoff value of sum of CN for <i>KRAS<\/i>, <i>ERBB3<\/i>, <i>CDK4<\/i>, and <i>MDM2. <\/i>for chromosome 12 set to 9, 8 (72.7%) of 11 patients with CN 9 or higher were in OR group, while 4 (7.7%) of 52 patients with CN less than 9 were in OR group, showing a significant difference between the two groups (<i>P &#60; <\/i>0.001). Similarly, when the cutoff value of sum of CN for <i>EGFR<\/i>, <i>MET<\/i>, and <i>BRAF <\/i>for chromosome 7 set to 8, 5 (83.3%) of 6 patients with CN 8 or higher were in OR group, while 7 (12.3%) of 57 patients with CN &#60; 8 were in OR group, showing a significant difference between the two groups (<i>P &#60; <\/i>0.001). On the other hand, genetic markers predicting susceptibility to ICI could not be identified. Kaplan-Meier analysis showed that the group of patients with higher CN values for either chromosome 7 or 12 had better PFS2 after TKI treatment than the group of patients with lower CN values for either chromosome 7 or 12 (P &#60; 0.001).<br \/>Conclusion: Our results from in-house cancer gene panel tests successfully showed an association between RCC progression and cancer-related gene alterations. Furthermore, the results showed the possibility of predicting TKI treatment sensitivity in mRCC by focusing on CN gain of oncogenes in specific chromosomal regions.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Renal cell carcinoma,Biomarkers,Drug sensitivity,Genome,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Akhito Takeuchi<\/b><sup>1<\/sup>, Mayu Takeda<sup>2<\/sup>, Eiji Sugihara<sup>3<\/sup>, Yoshinari Muto<sup>1<\/sup>, Sachio Nohara<sup>4<\/sup>, Shigeki Tanishima<sup>4<\/sup>, Kenji Zennami<sup>5<\/sup>, Kiyoshi Takahara<sup>5<\/sup>, Tetsuya Tsukamoto<sup>6<\/sup>, Ryoichi Shiroki<sup>5<\/sup>, Hideyuki Saya<sup>7<\/sup>, Makoto Sumitomo<sup>1<\/sup><br><br\/><sup>1<\/sup>Fujita Cancer Center and Department of Urology School of Medicine, Fujita Health University, Toyoake, Japan,<sup>2<\/sup>Fujita Cancer Center and Department of Medical Research for Intractable Disease, Fujita Health University, Toyoake, Japan,<sup>3<\/sup>Fujita Cancer Center and Research Promotion Headquarters, Open Facility Center, Fujita Health University, Toyoake, Japan,<sup>4<\/sup>Department of Bio Informatics, Communication Engineering Center, Electronic System Business Group, Mitsubishi Electric Software Corp., Tokyo, Japan,<sup>5<\/sup>Department of Urology School of Medicine, Fujita Health University, Toyoake, Japan,<sup>6<\/sup>Department of Pathology School of Medicine, Fujita Health University, Toyoake, Japan,<sup>7<\/sup>Fujita Cancer Center, Fujita Health University, Toyoake, Japan","CSlideId":"","ControlKey":"a8e30a32-aec2-426f-b9e5-38fe213c5207","ControlNumber":"1542","DisclosureBlock":"&nbsp;<b>A. Takeuchi, <\/b> None..<br><b>M. Takeda, <\/b> None..<br><b>E. Sugihara, <\/b> None..<br><b>Y. Muto, <\/b> None..<br><b>S. Nohara, <\/b> None..<br><b>S. Tanishima, <\/b> None..<br><b>K. Zennami, <\/b> None..<br><b>K. Takahara, <\/b> None..<br><b>T. Tsukamoto, <\/b> None..<br><b>R. Shiroki, <\/b> None..<br><b>H. Saya, <\/b> None..<br><b>M. Sumitomo, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4138","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4331","PresenterBiography":null,"PresenterDisplayName":"Akhito Takeuchi, No Degree","PresenterKey":"ad212709-637e-4cde-acec-211d080b2b09","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4331. Comprehensive analysis of copy number variation and sensitivity to targeted therapy in renal cell carcinoma using in-house cancer gene panel testing","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Comprehensive analysis of copy number variation and sensitivity to targeted therapy in renal cell carcinoma using in-house cancer gene panel testing","Topics":null,"cSlideId":""},{"Abstract":"Understanding the spatial complexities within cancer provides crucial information for evaluating individual tumor development and progression; recent research in prostate cancer has shown how critical it is for oncologists to maintain a spatial context while characterizing a highly heterogeneous tumor microenvironment. As more and more research groups acknowledge the need for spatial biology solutions to solve difficult questions surrounding cell identity, heterogeneity, and interaction, Vizgen&#8217;s MERSCOPE<sup>TM <\/sup>Platform provides a powerful tool to illuminate spatial information. Built on Multiplexed Error-Robust Fluorescence in situ Hybridization (MERFISH) technology, Vizgen&#8217;s MERSCOPE<sup>TM<\/sup> enables the direct profiling of the spatial organization of intact tissue with subcellular resolution. Here, we use a 500-gene panel to demonstrate the MERSCOPE&#8217;s spatial capability, assessing the canonical signaling pathways of cancer, cancer type-specific genes, select immune genes, proto-oncogenes, and tumor-suppressor genes in patient-derived prostate cancer samples. Using the Vizgen Cell Boundary Stain kit, we were able to generate a molecular and cellular atlas of these individual patient tumors by clustering cells based on gene expression and mapping these clusters back onto a spatial representation of the tumor. We found specific clusters relating to prognostic outcomes in cancer-associated fibroblasts (CAFs) and myofibroblasts. Subsequently, we used single-cell RNA-seq datasets to impute related transcriptome data for these various fibroblast clusters to help characterize them more specifically. To understand the heterogeneity intrinsic to CAFs, we performed a neighborhood analysis to determine how proximity to immune cells, tumor cells, and other stromal cells altered gene expression in different CAF clusters. We found gene expression changes associated with inflammation and reactive stromal signaling in CAFs based on their proximity to tumor versus stromal tissue compartments. We also compared the gene expression of tumor cells near CAFs to those more deeply embedded within the tumor compartment. This revealed interesting transcriptional covariations between superficial layers of tumor and their surrounding stromal milieu involved in cell proliferation and signaling. These analyses demonstrate the transcriptional variation possible across fibroblastic stromal cells acting in tumor-adjacent or stromal contexts. Notably, we were able to map and catalogue different patterns of gene expression relating to inflammation, tumor proliferation, and reactive stromal signaling. These findings demonstrate how the MERSCOPE platform can provide deep insights into the complex heterogeneity observed in the tumor microenvironment.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Prostate cancer,Cancer associated fibroblasts,Single cell,Imaging,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Ben Patterson<\/b><sup><\/sup>, Cheng-Yi Chen<sup><\/sup>, Nicolas Fernandez<sup><\/sup>, Simran Kaushal<sup><\/sup>, Leiam Colbert<sup><\/sup>, Jiang He<sup><\/sup><br><br\/>Vizgen, Cambridge, MA","CSlideId":"","ControlKey":"e23af675-ff9d-4c61-85c8-39e2c050b9bf","ControlNumber":"7397","DisclosureBlock":"&nbsp;<b>B. Patterson, <\/b> None..<br><b>C. Chen, <\/b> None..<br><b>N. Fernandez, <\/b> None..<br><b>S. Kaushal, <\/b> None..<br><b>L. Colbert, <\/b> None..<br><b>J. He, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4139","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4332","PresenterBiography":null,"PresenterDisplayName":"Ben Patterson, PhD","PresenterKey":"9ca64c66-d5b4-421a-963a-a1f0cf43f0bc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4332. Characterizing cancer-associated fibroblasts in prostate cancer using Vizgen&#8217;s MERSCOPE<sup>TM<\/sup> Platform","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Characterizing cancer-associated fibroblasts in prostate cancer using Vizgen&#8217;s MERSCOPE<sup>TM<\/sup> Platform","Topics":null,"cSlideId":""},{"Abstract":"Background: Recently, anti-PD-L1 in combination with cytotoxic chemotherapy has shown significant survival benefit in a randomized phase 3 trial for unresectable or metastatic biliary tract cancer (BTC). However, no biomarker including PD-L1 expression has been established to predict clinical outcomes, and there is an unmet need for a novel predictive biomarker for anti-PD-1 or PD-L1 therapy. Here, we assessed TILs using artificial intelligence (AI)-powered spatial analysis in advanced BTC treated with anti-PD-1 beyond 1<sup>st<\/sup> line treatment.<br \/>Methods: An AI-powered whole-slide image (WSI) analyzer (Lunit SCOPE IO, Lunit, Seoul, Korea) was used to segment tumor epithelium and stroma, and identification of intratumor TIL (iTIL) and stromal TIL (sTIL). H&#38;E stained WSI from pre-treatment samples was acquired from Asan Medical Center (n =166), and a total of 154 samples (92.8%) after quality control were used for the final analysis. Immune phenotypes (IP) were defined as follow: in&#64258;amed as high iTIL and sTIL; immune-excluded as low iTIL and high sTIL; immune-desert as low TIL overall. Among them, 20 patients were available for multi&#8209;color flow cytometry analysis (FACS) using peripheral blood mononuclear cells, collected at baseline, C1D8, and C2D1.<br \/>Results: All patients (n=154) were treated with anti-PD-1 (pembrolizumab or nivolumab) monotherapy, and 72 of 154 patients (46.8%) were treated as 2<sup>nd<\/sup> line. Gemcitabine plus cisplatin (GemCis) was used prior to anti-PD-1 as first-line therapy in all patients. Overall, 15 (9.7%) patients showed inflamed IP. With median follow-up duration of 15.4 months, the inflamed IP group showed better overall survival (17.2 vs. 6.6 months, P=0.03), and progression-free survival (PFS; 4.5 vs. 2.6 months, P=0.09) along with higher PFS rate at 12 months (33.3% vs. 11.5%, P=0.035), and overall response rate (26. 7% vs. 8.6%, P=0.053) than other phenotype groups. There was no significant difference in median PFS with GemCis among IP groups (P=0.74). In the FACS available subgroup, inflamed IP showed higher baseline central memory T (Tcm)+effector memory T (Tem)\/Tnaive ratio than other IPs. With the administration of anti-PD-1, Tcm+Tem\/Tnaive ratio was increased, while the proportion of PD1+CD8+T, CD39+CD8+T, CD103+CD8+T and Treg were decreased in the inflamed IP group than other phenotype groups.<br \/>Conclusions: Immune phenotypes classified by AI-powered spatial TIL analysis was effective to predict the clinical outcomes of patients with advanced BTC treated with anti-PD-1 therapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Biomarkers,Biliary tract cancer,Immunotherapy,Artificial intelligence,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Yeong Hak Bang<\/b><sup>1<\/sup>, Kyunghye Bang<sup>2<\/sup>, Jin Ho Shin<sup>3<\/sup>, Hyunseok Yoon<sup>4<\/sup>, Kyu-Pyo Kim<sup>1<\/sup>, Inkeun Park<sup>1<\/sup>, Jae Ho Jeong<sup>1<\/sup>, Heung-Moon Chang<sup>1<\/sup>, Baek-Yeol Ryoo<sup>1<\/sup>, Chiyoon Oum<sup>5<\/sup>, Seulki Kim<sup>5<\/sup>, Yoojoo Lim<sup>5<\/sup>, Gahee Park<sup>5<\/sup>, Chan-Young Ock<sup>5<\/sup>, Changhoon Yoo<sup>1<\/sup><br><br\/><sup>1<\/sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,<sup>2<\/sup>Division of Hemato-Oncology, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea, Republic of,<sup>3<\/sup>Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,<sup>4<\/sup>Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,<sup>5<\/sup>Lunit, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"8215ca68-26b3-4a12-860e-51fa45d855b9","ControlNumber":"1545","DisclosureBlock":"&nbsp;<b>Y. Bang, <\/b> None..<br><b>K. Bang, <\/b> None..<br><b>J. Shin, <\/b> None..<br><b>H. Yoon, <\/b> None..<br><b>K. Kim, <\/b> None..<br><b>I. Park, <\/b> None..<br><b>J. Jeong, <\/b> None..<br><b>H. Chang, <\/b> None..<br><b>B. Ryoo, <\/b> None.&nbsp;<br><b>C. Oum, <\/b> <br><b>Lunit<\/b> Employment. <br><b>S. Kim, <\/b> <br><b>Lunit<\/b> Employment. <br><b>Y. Lim, <\/b> <br><b>Lunit<\/b> Employment. <br><b>G. Park, <\/b> <br><b>Lunit<\/b> Employment. <br><b>C. Ock, <\/b> <br><b>Lunit<\/b> Employment, Stock, Stock Option.<br><b>C. Yoo, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4140","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"7","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4333","PresenterBiography":null,"PresenterDisplayName":"Yeong Hak Bang, MD","PresenterKey":"55ade2e5-1078-427a-a275-d0f929405bd1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4333. Spatial analysis of tumor-infiltrating lymphocytes in tumor microenvironment as biomarker for immune checkpoint inhibition in biliary tract cancer","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Spatial analysis of tumor-infiltrating lymphocytes in tumor microenvironment as biomarker for immune checkpoint inhibition in biliary tract cancer","Topics":null,"cSlideId":""},{"Abstract":"<b>Introduction:<\/b><b> <\/b>Clever-1 is an immunosuppressive scavenger receptor expressed on tumor associated macrophages. High levels of Clever-1 are associated with poor survival, T-cell exclusion and dysfunction, and immunotherapy resistance. Bexmarilimab (FP-1305) is a novel humanized anti-Clever-1 IgG4-antibody capable of promoting an immune switch, potentially leading to intratumoral proinflammatory responses in patients. In a first-in-human all-comer single agent Phase I\/II study in advanced solid tumors (NCT03733990) approximately 30% of patients in hepatocellular carcinoma, cutaneous melanoma and cholangiocarcinoma achieved immune activation, characterized by an IFNg response, which led to a survival benefit (ASCO 2022). Here, we show that patients getting a therapy benefit have immunologically cold tumors with low PD-L1 staining and high Clever-1 staining.<br \/><b>Methods:<\/b> Pre-treatment tumor samples were immunohistochemically stained for Clever-1 (4G9, Santa Cruz) using Ventana platform and scored by % of intratumoral positive cells out of all viable cells and PD-L1 (22C3, Agilent) with combined positivity scoring (CPS). Ratio (PD-L1\/Clever-1) at baseline was compared using non-parametric Wilcoxon-test according to clinical benefit.<br \/><b>Results:<\/b> 23 successful baseline biopsies and stainings were obtained, 6 per cutaneous melanoma, 11 per cholangiocarcinoma and 1 per hepatocellular carcinoma, from patients treated with bexmarilimab. Patients had received an average of three previous lines of therapy. At baseline, patients that saw a clinical benefit (CBR) from bexmarilimab had average PD-L1\/Clever-1 ratio of 0.2 compared to 4.4 (p=0.042, Wilcoxon nonparametric test) in patients that did not respond to the treatment.<br \/><b>Conclusion:<\/b> PD-L1\/Clever-1 IHC staining ratio may be used to predict bexmarilimab responding patients. These patients have a low PD-L1 staining and low IFNg levels as reported previously, and are often refractory to checkpoint inhibitors and other T cell activating agents. Bexmarilimab provides a novel therapy option for a tumor group that is otherwise poorly responsive to immune therapies.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Immunotherapy,Macrophages,Checkpoint Inhibitors,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Mari L. Björkman<sup>1<\/sup>, <b>Elisa  M.  Vuorinen<\/b><sup>1<\/sup>, Juho Jalkanen<sup>1<\/sup>, Marie-Louise Fjällskog<sup>1<\/sup>, Jussi Koivunen<sup>1<\/sup>, Teppo Huttunen<sup>2<\/sup>, Maija Hollmén<sup>3<\/sup>, Petri Bono<sup>4<\/sup><br><br\/><sup>1<\/sup>Faron Pharmaceuticals, Turku, Finland,<sup>2<\/sup>Estimates, Turku, Finland,<sup>3<\/sup>MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland,<sup>4<\/sup>Terveystalo, Helsinki, Finland","CSlideId":"","ControlKey":"b4c45a30-b971-4510-beea-5223873efc9b","ControlNumber":"6211","DisclosureBlock":"<b>&nbsp;M. L. Björkman, <\/b> <br><b>Faron Pharmaceuticals<\/b> Employment. <br><b>E. M. Vuorinen, <\/b> <br><b>Faron Pharmaceuticals<\/b> Employment. <br><b>J. Jalkanen, <\/b> <br><b>Faron Pharmaceuticals<\/b> Employment, Stock, Stock Option, Other Securities. <br><b>M. Fjällskog, <\/b> <br><b>Faron Pharmaceuticals<\/b> Employment. <br><b>J. Koivunen, <\/b> <br><b>Faron Pharmaceuticals<\/b> Employment. <br><b>T. Huttunen, <\/b> <br><b>Estimates<\/b> Other Business Ownership. <br><b>M. Hollmén, <\/b> <br><b>Faron Pharmaceuticals<\/b> Stock.<br><b>P. Bono, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4141","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4334","PresenterBiography":null,"PresenterDisplayName":"ELISA VUORINEN","PresenterKey":"5fab4121-fa47-443d-8200-71a72332ce74","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4334. Clever-1\/PD-L1 ratio predicts response to Bexmarilimab, a novel macrophage-guided immunotherapy, in immune deprived cancers","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Clever-1\/PD-L1 ratio predicts response to Bexmarilimab, a novel macrophage-guided immunotherapy, in immune deprived cancers","Topics":null,"cSlideId":""},{"Abstract":"Prostate cancer is the second most common cause of cancer-related deaths in American men. About 20-40% of patients with localized castration-sensitive prostate cancer (CSPC) eventually progress, requiring androgen deprivation therapy (ADT). However ADT inevitably fails, giving rise to castration-resistant prostate cancer (CRPC), which is incurable and fatal. A significant fraction of patients undergoing ADT die of treatment-accelerated cardiovascular disease. Pre-existing metabolic dysfunction has been implicated in PC disease incidence, higher rates of prostatectomy failure, and accelerated progression to CRPC. Thus, there is an unmet need to counter the adverse sequelae of ADT through alternative CSPC treatments that do not exacerbate metabolic syndrome but prevent PC progression. Few studies have evaluated whether targeting the metabolic dysfunction associated with early-stage PC can prevent progression and thus the need for ADT. In a recent clinical trial spearheaded by Dr. Bilusic, metformin, an affordable and well-tolerated insulin-sensitizing diabetes drug, has recently shown promise as monotherapy in biologically-recurrent CSPC, preventing PSA rise in about 40% of high-risk patients. To identify the molecular mechanisms and biomarkers of positive response to metformin in PC patients, we performed preliminary cytokine profiling of responder vs non-responder patient sera. We found that mitigation of inflammatory factors implicated in cardiovascular disease as well as markers of pro-apoptotic response are associated with positive metformin response. We also found that metformin responders exhibited pre-treatment cytokine signatures associated with inflammatory metabolic diseases, including diabetes and hyperinsulinemia, which are conditions known to benefit from metformin treatment. We have been able to model the variability of metformin treatment response in two well-characterized CSPC cell lines, LNCaP (highly responsive) and LAPC4 (minimally responsive). Metformin induced cell death in LNCaP but not in LAPC4, which possesses mutant p53 and high Bcl-2 levels. LAPC4 instead showed markers of senescence, which is associated with an inflammatory phenotype. Metformin also elevated levels of damaging high-potency (short-lived) ROS in LNCaP to a greater extent than in LAPC4. LAPC4 instead exhibited elevated levels of hydrogen peroxide upon metformin treatment, a ROS associated with inflammation. Thus the cell models show congruence with factors of positive response seen in patients. Our findings shed light on the potential mechanism of positive response to metformin in CSPC patients, and lay the groundwork for further investigation, while insight into biomarkers predicting positive response could be immediately useful in the clinic.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Prostate cancer,Metformin,Cytokines,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Philip Gregory<\/b><sup>1<\/sup>, Beatriz Mateo-Victoriano<sup>2<\/sup>, Ling Zhang<sup>1<\/sup>, Cassie Due<sup>3<\/sup>, Marijo Bilusic<sup>4<\/sup>, Priyamvada Rai<sup>5<\/sup><br><br\/><sup>1<\/sup>Radiation Oncology, University of Miami, Miami, FL,<sup>2<\/sup>Radiation Oncology, Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, FL,<sup>3<\/sup>College of Arts and Sciences, University of Miami, Miami, FL,<sup>4<\/sup>Department of Medical Oncology\/Department of Medicine, University of Miami, Miami, FL,<sup>5<\/sup>Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL","CSlideId":"","ControlKey":"db49ec07-a38c-4a8c-ae5f-5842ac00341e","ControlNumber":"3538","DisclosureBlock":"&nbsp;<b>P. Gregory, <\/b> None..<br><b>B. Mateo-Victoriano, <\/b> None..<br><b>L. Zhang, <\/b> None..<br><b>C. Due, <\/b> None..<br><b>M. Bilusic, <\/b> None..<br><b>P. Rai, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4142","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"9","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4335","PresenterBiography":null,"PresenterDisplayName":"Philip Gregory, BS,MS","PresenterKey":"ec549d97-bfd3-49cd-96e1-10745029a5de","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4335. Repurposing metformin in early-stage high risk prostate cancer to avoid ADT-induced cardiovascular toxicity","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Repurposing metformin in early-stage high risk prostate cancer to avoid ADT-induced cardiovascular toxicity","Topics":null,"cSlideId":""},{"Abstract":"The PD-1\/PD-L1 signaling pathway is essential for immune control and maintaining immune system balance. PD-1 and PD-L1 proteins exert most functions in cells and tissues by undergoing modifications and forming dynamic complexes <i>&#8211; <\/i>effects that cannot be explored by genomics, transcriptomics, or conventional immunostaining methods. Numerous cancer therapies are being developed that affect PD-1\/PD-L1 signaling, and tools to study the PD-1\/PD-L1 axis are, therefore, essential. One prerequisite for successfully establishing diagnostic assays is reproducibility, standardization, and, ideally, high sample throughput via automation. Here, we aimed to introduce a new technological solution to allow for the simultaneous detection of PD-L1 and PD-1 interaction and the adjacent immune cell context in tissue samples on the Lunaphore&#8217;s automated microfluidic staining platform. The assay for detecting PD-1-PD-L1 interaction was developed and technically validated by Navinci Diagnostics. Although the detection of interaction alone provided important information on the immune status in the tumor microenvironment, we believed that PD-1\/PD-L1 readout would be most powerful in the context of its cellular ecosystem. Therefore, the PD-1\/PD-L1 assay was combined with the analysis of immune and cancer cells to determine their involvement in this signaling. The feasibility of combining multiplex immunofluorescence with proximity ligation assay was conducted and confirmed on human tonsils. The spatial profiling panel included immune markers for all T-cells (CD3), helper T-cell (CD4), cytotoxic T-cells (CD8), B-cells (CD19\/20) and activation\/exhaustion markers granzyme B (activated cytotoxic T-cell), Ki67 (proliferating cells), and LAG3 (malignant B cells, CD8 T cells, CD4 T<sub>regs<\/sub>). We evaluated, implemented, and optimized the assays on the Lunaphore staining instrument to reduce labor time and cost for the end users. In the next phase, the potential of our assay to be benchmarked as a diagnostic tool in clinical praxis will be thoroughly tested and validated on diagnostic tissue samples from NSCLC patient cohorts. We believe this approach will enable spatial and functional studies of the interface between the tumor and the immune system and provide necessary information about signaling pathway activation in situ, the latest representing a novel state-of-the-art in tissue diagnostics.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"PD-1,PD-L1,Multiplex automation,Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Hampus Elofsson<sup>1<\/sup>, <b>Agata Zieba Wicher<\/b><sup>1<\/sup>, Carolina Oses Sepulveda<sup>2<\/sup>, Tony Ullman<sup>2<\/sup>, Maria-Giuseppina Procopio<sup>3<\/sup>, Alix Faillétaz<sup>3<\/sup>, Diego  G.  Dupouy<sup>3<\/sup>, Charlotte Stadler<sup>2<\/sup><br><br\/><sup>1<\/sup>R&D, Navinci Diagnostics AB, Uppsala, Sweden,<sup>2<\/sup>SciLife Lab, Royal Institute of Technology (KTH), Stockholm, Sweden,<sup>3<\/sup>R&D, Lunaphore Technologies S.A., Tolochenaz, Switzerland","CSlideId":"","ControlKey":"84b26291-bf7a-4c94-a681-5cc1a3ca0d0a","ControlNumber":"6117","DisclosureBlock":"&nbsp;<b>H. Elofsson, <\/b> None..<br><b>A. Zieba Wicher, <\/b> None..<br><b>C. Oses Sepulveda, <\/b> None..<br><b>T. Ullman, <\/b> None..<br><b>M. Procopio, <\/b> None..<br><b>A. Faillétaz, <\/b> None..<br><b>D. G. Dupouy, <\/b> None..<br><b>C. Stadler, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4143","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4336","PresenterBiography":null,"PresenterDisplayName":"Agata Zieba Wicher, D Phil","PresenterKey":"e03713dc-072c-415a-a2e8-6a24474a1863","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4336. Automation of proximity ligation immunoassay for interaction between PDL1 and PD1 detection in the tumor microenvironment using microfluidic based system","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Automation of proximity ligation immunoassay for interaction between PDL1 and PD1 detection in the tumor microenvironment using microfluidic based system","Topics":null,"cSlideId":""},{"Abstract":"PD-L1 immunohistochemistry (IHC) is routinely used to predict the clinical response to immune checkpoint inhibitors (ICIs); however, multiple assays and antibodies have been used. This study aimed to evaluate the potential of targeted transcriptome and artificial intelligence (AI) to determine PD-L1 RNA expression levels and predict the ICI response compared to traditional IHC. RNA from 396 solid tumors samples was sequenced using next-generation sequencing (NGS) with a targeted 1408-gene panel. RNA expression and PD-L1 IHC were assessed across a broad range of PD-L1 expression levels. The geometric mean na&#239;ve Bayesian (GMNB) classifier was used to predict the PD-L1 status. PD-L1 RNA levels assessed by NGS demonstrated robust linearity across high and low expression ranges, and those assessed using NGS and IHC (Tumor cells (TC), Tumor Proportion Score (TPS) and tumor-infiltrating immune cells (ICs) were highly correlated (Tables 1). RNA sequencing provided in-depth information on the tumor microenvironment and immune response, including CD19, CD22, CD8A, CTLA4, and PD-L2 expression status. Sub-analyses showed a sustained correlation of mRNA expression with IHC (TPS and ICs) across different solid tumor types. Machine learning showed high accuracy in predicting PD-L1 status, with the area under the curve varying between 0.988 and 0.920. Targeted transcriptome sequencing combined with AI is highly useful for predicting PD-L1 status. Measuring PD-L1 mRNA expression by NGS is comparable to measuring PD-L1 expression by IHC for predicting ICI response. RNA expression has the added advantages of being amenable to standardization and avoidance of interpretation bias, along with an in-depth evaluation of the tumor microenvironment.<br \/><table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{06F590D7-8CB0-4B17-B8E8-1A9965771B2F}\"><caption>Correlation between PD-L1 expression levels and PD-L1 IHC results<\/caption><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">IHC test results<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Variable<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Cases (N)<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>Mean<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Median<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Range<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Lower Quartile<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Upper Quartile<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">10th Percentile<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">90th Percentile<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>Std. Dev.<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TC&lt;1%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">223.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.49<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.97<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 25.99<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.79<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.73<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.07<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">9.16<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.32<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TC&gt;1%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">90.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">14.87<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">10.11<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.62 - 77.53<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.60<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">18.62<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.95<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">32.35<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">15.75<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TC&lt;10%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">267.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.17<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.36<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 72.72<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.94<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">6.43<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.14<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">10.71<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">6.14<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TC&gt;10%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">46.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">20.81<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">14.03<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.90 - 77.53<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">8.67<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">26.32<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.21<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">51.02<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">17.33<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">IC&lt;1%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">133.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.95<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.66<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 25.99<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.71<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.03<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.99<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">7.95<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.56<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">IC&gt;1%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">129.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">9.38<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.43<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.29 - 77.53<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.21<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">10.31<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.74<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">19.05<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">12.13<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">IC&lt;10%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">226.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.69<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.03<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 72.72<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.92<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">6.09<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.15<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">12.25<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">8.24<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">IC&gt;10%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">36.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">12.50<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">8.52<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.29 - 77.53<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.72<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">13.80<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.18<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">31.83<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">13.95<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TPS&lt;1%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">143.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.36<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.35<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 25.99<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.41<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.58<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.53<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">7.40<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.87<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TPS&gt;1%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">207.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">10.19<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.63<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.29 - 133.81<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.03<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">11.65<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.74<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">22.25<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">14.74<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TPS&lt;10%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">252.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.25<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.87<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 72.72<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.74<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.96<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.92<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">8.70<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.81<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TPS&gt;10%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">98.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">15.50<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">9.67<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.29 - 133.81<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">4.91<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">18.74<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.90<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">31.87<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">18.57<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TPS&lt;30%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">319.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">5.35<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">3.32<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">0.00 - 72.72<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.94<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">6.43<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">1.06<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">12.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">6.48<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">TPS&gt;30%<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">CD274<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">31.00<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">28.50<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">18.62<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">2.90 - 133.81<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">11.47<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">35.94<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">6.67<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">52.69<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:107%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">27.31<\/span><\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,Cancer immunotherapy,Machine learning,PD-L1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Ahmad Charifa<\/b><sup>1<\/sup>, Alfonso Lam<sup>1<\/sup>, Hong Zhang<sup>1<\/sup>, Andrew Ip<sup>2<\/sup>, Andrew Pecora<sup>2<\/sup>, Stanley Waintraub<sup>2<\/sup>, Deena Graham<sup>2<\/sup>, Donna McNamara<sup>2<\/sup>, Martin Gutierrez<sup>2<\/sup>, Andrew Jennis<sup>2<\/sup>, Ipsa Sharma<sup>1<\/sup>, Jeffrey Estella<sup>1<\/sup>, Wanlong Ma<sup>1<\/sup>, Andre Goy<sup>2<\/sup>, Maher Albitar<sup>1<\/sup><br><br\/><sup>1<\/sup>Genomic Testing Cooperative, Irvine, CA,<sup>2<\/sup>John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ","CSlideId":"","ControlKey":"4934091d-1e84-4536-8558-60b3ec2c9b8d","ControlNumber":"2319","DisclosureBlock":"<b>&nbsp;A. Charifa, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment. <br><b>A. Lam, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment. <br><b>H. Zhang, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment.<br><b>A. Ip, <\/b> None..<br><b>A. Pecora, <\/b> None..<br><b>S. Waintraub, <\/b> None..<br><b>D. Graham, <\/b> None..<br><b>D. McNamara, <\/b> None..<br><b>M. Gutierrez, <\/b> None..<br><b>A. Jennis, <\/b> None.&nbsp;<br><b>I. Sharma, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment. <br><b>J. Estella, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment. <br><b>W. Ma, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment.<br><b>A. Goy, <\/b> None.&nbsp;<br><b>M. Albitar, <\/b> <br><b>Genomic Testing Cooperative<\/b> Employment.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4144","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"11","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4337","PresenterBiography":null,"PresenterDisplayName":"Ahmad Charifa, MD","PresenterKey":"0be09ea8-e228-4e12-86f1-70d507e57cec","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4337. Predicting PD-L1 status in solid tumors using transcriptomic data and artificial intelligence algorithms","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Predicting PD-L1 status in solid tumors using transcriptomic data and artificial intelligence algorithms","Topics":null,"cSlideId":""},{"Abstract":"<b>Introduction<\/b>: Microsatellite instability (MSI) arises when short tandem DNA repeat sequences undergo a length change due to impaired mismatch repair (MMR). MSI is present in many cancers and is an approved biomarker for immune checkpoint inhibitor therapy. In this study, we used 71 clinical specimens to evaluate a new droplet digital (ddPCR) method to assess MSI in tissue and in plasma. The ddPCR assay is designed to detect mutations in BAT25, BAT26, NR21, NR24 and Mono27, and is intended for use in FFPE. Our evaluation extended these analyses to cfDNA in plasma.<br \/><b>Methods<\/b>: DNA was extracted from ten (10) CRC FFPE samples, fifty-two (52) CRC liquid biopsies, and ten (10) Normal Healthy Donors (NHD) and tested using the new assay. DNA extracts were quantified by fluorescence, and duplicate ddPCR reactions were performed using 2.6 ng input DNA per well. MSI status was determined with a pre-commercial release auto-calling analysis software, which makes a positive call (MSI-High) when two or more of the five MSI markers (<u>&#62;<\/u> 40%) are detected. Markers are called positive if the fractional abundance or copy number is greater than the previously established limit of blank (LOB) in FFPE and plasma, respectively. For FFPE, the LOBs (%) are 2.11 (BAT25), 0.34 (BAT26), 2.38 (NR21), 1.51 (NR24) and 0.56 (Mono27) based on analytic specimen evaluation. For plasma, a marker is positive if one (1) mutant copy is detected.<br \/><b>Results<\/b>: All 10 FFPE samples were deemed to be concordant with the reference Promega PCR assay at the microsatellite evaluation level. Additionally, the 8 cfDNA samples with reference MSI status yielded 87.5% (7\/8) concordant results for microsatellite loci status. A survey of 44 plasma colorectal donor samples and 10 NHD samples with no reference results, yielded various microsatellite status as expected. The auto calling module for microsatellite loci status in these plasma samples accurately called 85.2 status (n = 54). At the marker level, 87% of BAT25, 98.1% of BAT26, 92.6% of NR21, 79.6% of NR24, and 61.1% of Mono27 calls were concordant between auto-calling and expert review.<br \/><b>Conclusion<\/b>: The new droplet digital MSI assay coupled with an automated calling module for MSI Status provides a convenient, cost-effective, and reproducible laboratory test method to determine MSI status in FFPE specimens. The utility of the test method and auto calling method for detection of MSI in cfDNA is less clear, with heterogenous clusters that require expert review appearing more often than in FFPE samples.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Mismatch repair,Diagnostic marker,Cancer markers,Microsatellite instability,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Sarah Kreston<\/b><sup><\/sup>, Mai Ho<sup><\/sup>, Claire Gould<sup><\/sup>, Ubaradka Sathyanarayana<sup><\/sup>, Brittany D'Alessio<sup><\/sup>, Janice Riley<sup><\/sup>, Gary A. Pestano<sup><\/sup><br><br\/>Biodesix, Inc., Boulder, CO","CSlideId":"","ControlKey":"d45ee36f-8b02-4879-bff1-76450ba4c973","ControlNumber":"7345","DisclosureBlock":"<b>&nbsp;S. Kreston, <\/b> <br><b>Biodesix<\/b> Employment. <br><b>M. Ho, <\/b> <br><b>Bio-Rad<\/b> Employment. <br><b>C. Gould, <\/b> <br><b>Biodesix<\/b> Employment. <br><b>U. Sathyanarayana, <\/b> <br><b>Biodesix<\/b> Employment. <br><b>B. D'Alessio, <\/b> <br><b>Biodesix<\/b> Employment. <br><b>J. Riley, <\/b> <br><b>Biodesix<\/b> Employment. <br><b>G. A. Pestano, <\/b> <br><b>Biodesix<\/b> Employment, Stock, Stock Option.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4146","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"12","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4339","PresenterBiography":null,"PresenterDisplayName":"Sarah Kreston, BS","PresenterKey":"6ee794d2-242e-47e0-b040-289984d4578d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4339. Development of new droplet digital PCR method for MSI assessment with automated analysis pipeline shows concordance in FFPE and plasma","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Development of new droplet digital PCR method for MSI assessment with automated analysis pipeline shows concordance in FFPE and plasma","Topics":null,"cSlideId":""},{"Abstract":"Immune check point blockade (ICB) has recently transformed the treatment of non-small cell lung (NSCLC). However, the majority of patients do not respond to ICB. For ICB to be effective, tumor neoantigens need to be presented in a human leukocyte antigen (HLA) class I-restricted manner. Recent studies by our group and others have shown that HLA-B44 supertype is associated with extended survival in patients treated with ICB. Herein, we hypothesize that HLA-B44-specific motif neoepitopes generate an active tumor immune microenvironment and a favorable ICB response in NSCLC. Utilizing the TCGA database, we found that nearly half of the NSCLC patients have at least one HLA-B44 allele, of whom 36.8% and 37.3% of patients harbor at least one B44 motif neoepitope in lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC), respectively. In a pooled analysis of patients with LUAD and LUSC, gene expression of <i>PD-L1<\/i>, <i>CTLA-4<\/i>, <i>LAG-3<\/i>, <i>CXCL9<\/i>, <i>CXCL10<\/i>, <i>CXCL13<\/i>, <i>CD8A<\/i> and cytolytic gene signature (includes <i>GZMA<\/i> and <i>PRF1<\/i>) is elevated in patients with B44 motif neoepitopes compared to those without motif neoepitopes. Immune cell component analysis showed increased infiltration of Th1, Th2 and CD8 T cells in LUAD and regulatory and CD8 T cells in LUSC. Although a linear regression model revealed a positive correlation between tumor mutational burden (TMB) and number of B44 motif neoepitopes, pooled analysis of LUAD and LUSC with similar TMB showed significant elevation of <i>CTLA-4<\/i>, <i>LAG3<\/i>, <i>CXCL10<\/i> and a trend of increased expression of <i>CXCL9<\/i> in motif patients. Upon investigation of possible immune editing, we found a significantly higher proportion of genes containing B44 neoepitope downregulated at the RNA level both in LUAD and LUSC. Lastly, we showed that combining B44 motif with either PD-L1 or TMB improved prediction of progression-free survival in NSCLC patients treated with ICB. In summary, we demonstrate that HLA-B44 motif neoepitopes are associated with a favorable tumor immune microenvironment and can serve as a potential biomarker for ICB benefit in NSCLC patients.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,HLA-B44,Immune checkpoint blockade,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Rui Li<\/b><sup>1<\/sup>, Charlene  M.  Fares<sup>2<\/sup>, Tristan  R.  Grogan<sup>3<\/sup>, Tianhao Zhang<sup>4<\/sup>, Debory Li<sup>5<\/sup>, Matthew Theisen<sup>6<\/sup>, Maria  A.  Velez<sup>7<\/sup>, Paige  M.  Brodrick<sup>7<\/sup>, Jackson  P.  Lind-Lebuffe<sup>7<\/sup>, Yazeed Radwan<sup>7<\/sup>, Gregory  A.  Ayzenberg<sup>7<\/sup>, David Elashoff<sup>3<\/sup>, Bin Liu<sup>8<\/sup>, Aaron  E.  Lisberg<sup>7<\/sup>, Amy  L.  Cumming<sup>7<\/sup>, Edward  B.  Garon<sup>7<\/sup><br><br\/><sup>1<\/sup>Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA,<sup>2<\/sup>Allina Health Cancer Institute, Saint Paul, MN,<sup>3<\/sup>General Internal Medicine and Health Services Research, UCLA David Geffen School of Medicine, Los Angeles, CA,<sup>4<\/sup>Molecular Biology, UCLA David Geffen School of Medicine, Los Angeles, CA,<sup>5<\/sup>Medicine, Western University of Health Sciences, Los Angeles, CA,<sup>6<\/sup>Kensho Technologies, Los Angeles, CA,<sup>7<\/sup>Hematology\/Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA,<sup>8<\/sup>Pulmonary and Critical Care, UCLA David Geffen School of Medicine, Los Angeles, CA","CSlideId":"","ControlKey":"79b58e7e-2d91-4f49-a737-8d325c5611fb","ControlNumber":"922","DisclosureBlock":"&nbsp;<b>R. Li, <\/b> None..<br><b>C. M. Fares, <\/b> None..<br><b>T. R. Grogan, <\/b> None..<br><b>T. Zhang, <\/b> None..<br><b>D. Li, <\/b> None..<br><b>M. Theisen, <\/b> None..<br><b>M. A. Velez, <\/b> None..<br><b>P. M. Brodrick, <\/b> None..<br><b>J. P. Lind-Lebuffe, <\/b> None..<br><b>Y. Radwan, <\/b> None..<br><b>G. A. Ayzenberg, <\/b> None..<br><b>D. Elashoff, <\/b> None..<br><b>B. Liu, <\/b> None.&nbsp;<br><b>A. E. Lisberg, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consultant. <br><b>Bristol-Myers Squibb<\/b> Other, Consultant. <br><b>Leica Biosystems<\/b> Other, Consultant. <br><b>Jazz Pharmaceuticals<\/b> Other. <br><b>Novocure<\/b> Other, Consultant. <br><b>Pfizer<\/b> Other, Consultant. <br><b>MorphoSys<\/b> Other, Consultant. <br><b>Eli-Lily<\/b> Other, Consultant. <br><b>Oncocyte<\/b> Other, Consultant. <br><b>Novartis<\/b> Other, Consultant. <br><b>Regeneron<\/b> Other, Consultant. <br><b>Janssen oncology<\/b> Other, Consultant. <br><b>Sanofi group of companies<\/b> Other, Consultant. <br><b>Daiichi Sankyo<\/b> Grant\/Contract. <br><b>Calithera Biosciences<\/b> Grant\/Contract. <br><b>Dracen Pharmaceuticals<\/b> Grant\/Contract. <br><b>WindMIL<\/b> Grant\/Contract. <br><b>eFFECTOR Therapeutics<\/b> Grant\/Contract. <br><b>A. L. Cumming, <\/b> <br><b>TEMPUS<\/b> Other, Consultant. <br><b>E. B. Garon, <\/b> <br><b>ABL-Bio<\/b> Grant\/Contract, Other, Consultant. <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consultant. <br><b>Boehringer-Ingelheim<\/b> Other, Consultant. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consultant. <br><b>Dracen Pharmaceuticals<\/b> Other, Consultant. <br><b>EMD Serono<\/b> Grant\/Contract, Other, Consultant. <br><b>Eisai<\/b> Other, Consultant. <br><b>Eli Lily<\/b> Grant\/Contract, Other, Consultant. <br><b>GSK<\/b> Other, Consultant. <br><b>Ipsen<\/b> Other, Consultant. <br><b>Merck<\/b> Grant\/Contract, Other, Consultant. <br><b>Natera<\/b> Other, Consultant. <br><b>Novartis<\/b> Grant\/Contract, Other, Consultant. <br><b>Personalis<\/b> Other, Consultant. <br><b>Regeneron<\/b> Other, Consultant. <br><b>Sanofi<\/b> Other, Consultant. <br><b>Shionogi<\/b> Other, Consultant. <br><b>Xilio<\/b> Other, Consultant. <br><b>Dynavax Technologies<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4147","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"13","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4340","PresenterBiography":null,"PresenterDisplayName":"Rui Li, MD;PhD","PresenterKey":"8b02dfeb-f5da-460a-b5e8-c4fbd8c1bacb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4340. HLA-B44 motif neoepitope is associated with a favorable tumor immune microenvironment and predicts ICB response in NSCLC","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"HLA-B44 motif neoepitope is associated with a favorable tumor immune microenvironment and predicts ICB response in NSCLC","Topics":null,"cSlideId":""},{"Abstract":"<b>Background:<\/b> Immune checkpoint inhibitors (ICI) has revolutionized the management of patients with non-small cell lung cancer (NSCLC). However, most patients with advanced NSCLC patients displayed primary resistance to ICI. Indoleamine 2,3-dioxygenase 1 (IDO1) may play a role in primary resistance by catabolizing tryptophan to several immunosuppressive metabolites such as kynurenine. The aim of our study was to investigate the role of IDO1 expression in the outcome of NSCLC patients treated with immunotherapy.<br \/><b>Methods<\/b>: We analyzed the largest NSCLC gene expression (GE) dataset worldwide including 891 pre-treatment tumors from POPLAR and OAK studies, two RCT assessing the efficacy of atezolizumab vs docetaxel in NSCLC. We then confirm our findings with multiplex immunofluorescence (mIF) and digital pathology analysis to investigate the correlation between expression of IDO1 by tumor cells and spatial distribution of CD8+ T cells.<br \/><b>Results<\/b>: The PFS of IDO1<sup>high<\/sup> patients was significantly higher than IDO1<sup>low<\/sup> (3.81 vs 1.89months, p=7.13e-09). Strikingly, high IDO1 expression was also associated with better ORR (19.9% vs 5.2%, p=9.93e-05) and improved OS (15.9 vs 9.65 months, p=6.35e-06). When adjusting for covariates (histological subtype, TLS signature, PD-L1 expression), IDO1 remained independently associated with PFS (HR 1.54, p=4.1e-4) and OS (HR 1.43, p=8.2e-3). None of these correlations were observed in the docetaxel arm, suggesting a predictive value of IDO1 GE specifically for response to atezolizumab. Using a deconvolution approach, the tumor microenvironment composition differed significantly between IDO1<sup>high<\/sup> and IDO1<sup>low<\/sup> tumors. Indeed, IDO1<sup>high<\/sup> tumors were characterized by the highest expression of genes specific to immune populations such as interferon-gamma-producing T helper 1 (Th1) cells, CD8+ T cells, natural killer cells, cytotoxic lymphocytes, and B cells. To further validate our findings, we performed mIF on 53 NSCLC tumors. Overall, elevated IDO1 expression by tumor cells was correlated with increased CD8+\/PD1+ T cells infiltration (p=0.001). Spatial cell distribution analysis also revealed that the relative distance between tumor cells and CD8+ T cells was significantly lower in IDO1<sup>high<\/sup> compared to IDO1<sup>low<\/sup> patients. Interestingly, 52% of tumors were characterized by the presence of TLS and IDO1 was observed in most TLS analyzed.<br \/><b>Conclusions<\/b>: IDO1 expression by tumor cells in NSCLC is associated with improved outcome in patients with NSCLC, independently of PDL1 expression score. IDO1 overexpression in NSCLC is associated with increased immune activity and may represent a negative feedback mechanism to CD8+ T cell infiltration.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"IDO,Immune checkpoint blockade,NSCLC,Immuno-oncology,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Jean-Philippe Guegan<\/b><sup>1<\/sup>, Florent Peyraud<sup>2<\/sup>, Christophe Rey<sup>1<\/sup>, Oren Ngouala<sup>1<\/sup>, Ophélie Odin<sup>1<\/sup>, Imane Nafia<sup>1<\/sup>, Isabelle Soubeyran<sup>2<\/sup>, Sylvestre Le Moulec<sup>3<\/sup>, Alban Bessede<sup>1<\/sup>, Antoine Italiano<sup>2<\/sup><br><br\/><sup>1<\/sup>Explicyte, Bordeaux, France,<sup>2<\/sup>Institute Bergonié, Bordeaux cedex, France,<sup>3<\/sup>Clinique Marzet, Pau, France","CSlideId":"","ControlKey":"42d1b51e-917a-43b6-8217-8e7c0e27a95d","ControlNumber":"5144","DisclosureBlock":"&nbsp;<b>J. Guegan, <\/b> None..<br><b>F. Peyraud, <\/b> None..<br><b>C. Rey, <\/b> None..<br><b>O. Ngouala, <\/b> None..<br><b>O. Odin, <\/b> None..<br><b>I. Nafia, <\/b> None..<br><b>I. Soubeyran, <\/b> None..<br><b>S. Le Moulec, <\/b> None..<br><b>A. Bessede, <\/b> None..<br><b>A. Italiano, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4148","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4341","PresenterBiography":null,"PresenterDisplayName":"Jean-Philippe Guegan, PhD","PresenterKey":"fccf0e0d-cf24-415a-9395-a67a9a883802","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4341. Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1\/PDL1 inhibitors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1\/PDL1 inhibitors","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Offering the optimal frontline treatment to a patient with acute myeloid leukemia (AML) requires trading off expected benefit and risk. Typical standard of care intensive induction chemotherapy (e.g., cytarabine plus idarubicin (7+3)) results in high clinical response rates. However, many patients receive a less intensive regimen (e.g., venetoclax plus decitabine (VenDec)) because their individual toxicity risk is high based on lack of medical fitness. Predicting an individual patient&#8217;s clinical response prior to treatment has the potential to increase the benefit\/risk ratio (therapeutic index) for some patients and optimize their treatment selection. Here, we demonstrate the ability of an automated high-throughput, multi-color flow cytometry predictive precision medicine platform (PPMP) to predict response to 7+3 or VenDec.<br \/>Methods: To assess correlation between PPMP-predicted and actual clinical response to 7+3 or VenDec in clinical trial NCT04263181, pre-induction blood samples were collected from 31 patients of which 18 received 7+3 (all newly diagnosed (ND) AML) and 13 VenDec (7 ND AML, 5 secondary AML, 1 MDS). We measured drug effects on leukemic blasts by applying a cutoff at the total blast count that optimizes separation between predicted responders and non-responders (&#8220;conventional approach&#8221;) or by a machine learning (ML) approach considering multiple cell populations. For the former approach, training sets represented 13 patients for 7+3 and 8 for VenDec. Both 7+3 and VenDec models were validated with 5 patients. For the ML approach, the model was trained on all 13 VenDec patients and monitored using leave-one-out cross-validation.<br \/>Results: For the conventional approach, predicted and true clinical responses were highly correlated for 7+3 (AUC = 0.91) and VenDec (AUC = 0.81), with 100% precision (positive predictive values (PPV)) for both, i.e., all predicted responders were true clinical responders. Some true clinical responders were not identified (negative predictive value (NPV) = 67% for 7+3 and 57% for VenDec), resulting in an accuracy of 94% (7+3) and 77% (VenDec). To maximize NPV and accuracy for predicting VenDec clinical outcomes, we applied a novel ML-based algorithm to integrate the behavior of malignant and non-malignant cell populations, yielding a model with 100% accuracy (100% PPV and NPV). Additional outcome data, including overall survival, are under evaluation.<br \/>Summary: Total blast-based predictions yielded accuracies of 94% for 7+3 and 77% for VenDec. An ML algorithm for VenDec considering additional cell populations increased the accuracy to 100%. Further studies will expand patient numbers. We plan to use this platform to inform our frontline decision making with the goal to maximize the therapeutic benefit\/risk ratio and ensure that the most appropriate frontline therapy is used for each individual patient.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Precision medicine,Predictive biomarkers,Acute myeloid leukemia,Machine learning,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Meagan  A.  Jacoby<\/b><sup>1<\/sup>, John  S.  Welch<sup>2<\/sup>, Peter Westervelt<sup>1<\/sup>, Matthew Christopher<sup>1<\/sup>, Geoffrey  L.  Uy<sup>1<\/sup>, Ravi Vij<sup>1<\/sup>, Keith  E.  Stockerl-Goldstein<sup>1<\/sup>, Brad  S.  Kahl<sup>1<\/sup>, Iskra Pusic<sup>1<\/sup>, John  F.  DiPersio<sup>3<\/sup>, Mark  A.  Schroeder<sup>1<\/sup>, Miriam  Y.  Kim<sup>1<\/sup>, Todd  A.  Fehniger<sup>1<\/sup>, Armin Ghobadi<sup>1<\/sup>, Christine  J.  Gu<sup>4<\/sup>, Wade Anderson<sup>4<\/sup>, Kathryn Vanderlaag<sup>4<\/sup>, Kamran Ali<sup>4<\/sup>, Camille Pataki<sup>4<\/sup>, Markus  D.  Lacher<sup>4<\/sup><br><br\/><sup>1<\/sup>Department of Medicine, Washington University, Saint Louis, MO,<sup>2<\/sup>Washington University, Saint Louis, MO,<sup>3<\/sup>Department of Internal Medicine, Washington University, Saint Louis, MO,<sup>4<\/sup>Notable Labs, Foster City, CA","CSlideId":"","ControlKey":"d514f3d5-6a30-464b-b85f-94eb0af26008","ControlNumber":"2298","DisclosureBlock":"&nbsp;<b>M. A. Jacoby, <\/b> None..<br><b>J. S. Welch, <\/b> None..<br><b>P. Westervelt, <\/b> None..<br><b>M. Christopher, <\/b> None..<br><b>G. L. Uy, <\/b> None.&nbsp;<br><b>R. Vij, <\/b> <br><b>Takeda<\/b> Other, Consultancy. <br><b>Oncopeptides<\/b> Other, Consultancy. <br><b>Harpoon<\/b> Other, Consultancy. <br><b>Sanofi<\/b> Other, Consultancy. <br><b>GSK<\/b> Other, Consultancy. <br><b>Pfizer<\/b> Other, Consultancy. <br><b>BMS<\/b> Other, Consultancy. <br><b>Legend<\/b> Other, Consultancy. <br><b>Janssen<\/b> Other, Consultancy. <br><b>Biogene<\/b> Other, Consultancy.<br><b>K. E. Stockerl-Goldstein, <\/b> None.&nbsp;<br><b>B. S. Kahl, <\/b> <br><b>AstraZeneca<\/b> Other, Consultancy and Research Funding. <br><b>ADT Therapeutics<\/b> Other, Consultancy. <br><b>Roche<\/b> Other, Consultancy. <br><b>Genentech<\/b> Other, Consultancy and Research Funding. <br><b>Abbvie<\/b> Other, Consultancy and Research Funding. <br><b>MEI<\/b> Other, Consultancy. <br><b>AcertaPharma<\/b> Other, Consultancy. <br><b>Pharmacyclics<\/b> Other, Consultancy. <br><b>Celgene\/BMS<\/b> Other, Consultancy and Research Funding. <br><b>Beigene<\/b> Other, Consultancy and Research Funding. <br><b>Kite<\/b> Other, Consultancy. <br><b>Janssen<\/b> Other, Consultancy. <br><b>Incyte<\/b> Other, Consultancy. <br><b>Hutchmed<\/b> Other, Consultancy and Research Funding. <br><b>TG Therapeutics<\/b> Other, Consultancy. <br><b>Genmab<\/b> Other, Consultancy. <br><b>Seattle Genetics<\/b> Other, Consultancy. <br><b>Research to Practice<\/b> Other, Speakers Bureau.<br><b>I. Pusic, <\/b> None.&nbsp;<br><b>J. F. DiPersio, <\/b> <br><b>Magenta Therapeutics<\/b> Patent, Other, Equity holder and Membership on Board of Directors or advisory committee(s).\u000d\u000aVLA-4 Inhibitor with Washington University and Magenta Therapeutics (category Patents & Royalties).. <br><b>WUGEN<\/b> Other, Equity holder and Research Funding.\u000d\u000aCAR-T cell Product with Washington University and WUGEN (category Patents & Royalties).. <br><b>Incyte<\/b> Other, Consultancy and Research Funding. <br><b>RiverVest Venture Partners<\/b> Other, Consultancy and Membership on Board of Directors or advisory committee(s).. <br><b>hC Bioscience, Inc.<\/b> Other, Membership on Board of Directors or advisory committee(s).. <br><b>Amphivena Therapeutics<\/b> Other, Research Funding. <br><b>NeoImmune Tech<\/b> Other, Research Funding. <br><b>Macrogenics<\/b> Other, Research Funding. <br><b>BioLineRx, Ltd.<\/b> Other, Research Funding. <br><b>M. A. Schroeder, <\/b> <br><b>Incyte<\/b> Other, Research Funding. <br><b>Genentech Inc<\/b> Other, Research Funding. <br><b>Cellect Inc<\/b> Other, Research Funding. <br><b>Fortis<\/b> Other, Research Funding. <br><b>Seagen Inc.<\/b> Other, Research Funding. <br><b>Amgen<\/b> Other, Research Funding. <br><b>Celgene<\/b> Other, Research Funding.<br><b>M. Y. Kim, <\/b> None.&nbsp;<br><b>T. A. Fehniger, <\/b> <br><b>Wugen<\/b> Stock Option, Other, Consultancy and Patents & Royalties (category). <br><b>Affimed<\/b> Other, Scientific Advisory Board and Research Funding. <br><b>Indapta<\/b> Stock Option, Other, Scientific Advisory Board. <br><b>Orca Bio<\/b> Stock Option. <br><b>HCW Biologics<\/b> Other, Research Funding. <br><b>ImmunityBio<\/b> Other, Research Funding. <br><b>BMS<\/b> Other, Provision of drug for investigator initiated trial. <br><b>A. Ghobadi, <\/b> <br><b>Kite, a Gilead Company<\/b> Other, Consultancy, Honoraria and Research Funding. <br><b>Amgen<\/b> Other, Consultancy and Research Funding. <br><b>Atara<\/b> Other, Consultancy. <br><b>Wugen Inc<\/b> Other, Consultancy. <br><b>Celgene<\/b> Other, Consultancy. <br><b>CRISPR Therapeutics<\/b> Other, Consultancy. <br><b>Genentech<\/b> Other, Research Funding. <br><b>C. J. Gu, <\/b> <br><b>Notable Labs<\/b> Employment, Stock Option. <br><b>W. Anderson, <\/b> <br><b>Notable Labs<\/b> Employment, Stock Option. <br><b>K. Vanderlaag, <\/b> <br><b>Notable Labs<\/b> Other, Ended employment in past 24 months. <br><b>K. Ali, <\/b> <br><b>Notable Labs<\/b> Other, Ended employment in the past 24 months. <br><b>C. Pataki, <\/b> <br><b>Notable Labs<\/b> Employment. <br><b>M. D. Lacher, <\/b> <br><b>Notable Labs<\/b> Employment, Stock Option.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4149","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"15","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4342","PresenterBiography":null,"PresenterDisplayName":"Meagan Jacoby, MD","PresenterKey":"ebd23e19-049f-4680-9e85-1fa999a16bff","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4342. Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes","Topics":null,"cSlideId":""},{"Abstract":"Two well-characterized EGFR inhibitor (EGFRi) therapies (cetuximab, panitumumab) have been FDA approved for metastatic colorectal cancer (CRC). Unfortunately, the extended RAS\/RAF testing required in the drug labels, identifies only non-responders, and only ~50% of treated patients will respond to therapy. Thus, there is an unmet need to develop additional biomarkers to identify EGFRi sensitive patients. Using an innovative hybrid approach fusing gene expression and DNA sequencing, we recently reported that combined mutations in <i>APC<\/i> and <i>TP53<\/i> were strongly correlated with a validated gene expression signature measuring cetuximab sensitivity in CRC human tumors (Yang et al. <i>Cancer Epidemiol Biomarkers Prev. <\/i>2019), suggesting a potential positive biomarker role of <i>APC<\/i> + <i>TP53<\/i> mutations. This finding prompted us to develop a DNA test designed to positively select EGFRi-responsive patients as augmentation to currently used negative predictors for CRC patients. By leveraging the TwinStrand Duplex Sequencing (DS) technology, we recently developed an ultrasensitive custom 6-gene panel (<i>APC, TP53, KRAS, BRAF, NRAS<\/i>, and <i>HRAS<\/i>) CLIA-certified assay for FFPE CRC tissues. The assay has been analytically validated using reference cell lines (n=10) which were individually sequenced to &#62;3,000x Duplex depth. The 6-gene DS assay yielded exceptionally high assay performance: (1) accuracy (passed, r<sup>2<\/sup> = 0.98 for Duplex VAF vs. target VAF for Positive Control mutations); (2) sensitivity (passed, all mutations &#62;1\/5,000 were detected in all Positive Control replicates; 1 mutation at 1\/5,000 was detected in 2\/3 replicates), (3) specificity (passed, 2 mutations detected in the Negative Control at 1 count in 1 replicate; VAF &#60;1\/10,000), and (4) precision (passed, &#60;2-fold variation among Positive Control replicates for VAF &#62;1\/500). Importantly, the validation analysis on fresh frozen (FF):FFPE paired tissues from 21 CRC patients shows: (1) The 6-gene DS assay performed on FFPE samples faithfully reproduces assay results on FF samples; (2) The ultrasensitive DS assay can accurately detect additional &#8220;new&#8221; mutations at low allelic frequencies compared to a standard NGS method. TwinStrand DS identified 17 mutations not identified by standard NGS; 13 of these new mutations had &#60; 10% VAF. Furthermore, preliminary Kaplan-Meier analysis of the third-line EGFRi data shows that while the statistical significance was not achieved due to the small simple size (n=28), patients harboring combined <i>APC<\/i> and <i>TP53<\/i> mutations(AP) (vs non-AP patients) tended to have longer progression free survival (6.65 vs 3.95 months, P=0.064) and overall survival (17.80 vs 10.65 months, P=0.14). Additional data acquisition and analysis is ongoing. Thus, there is an opportunity to change clinical practice and standards of care to ultimately improve CRC outcomes if this new, robust, sensitive test is clinically-validated.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Colorectal cancer,Biomarkers,Mutations,Assay development,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Mingli Yang<\/b><sup>1<\/sup>, Michael  J.  Schell<sup>2<\/sup>, Lance Pflieger<sup>3<\/sup>, Jesse Salk<sup>4<\/sup>, Timothy  J.  Yeatman<sup>1<\/sup><br><br\/><sup>1<\/sup>Department of Surgery, University of South Florida, Tampa, FL,<sup>2<\/sup>Moffitt Cancer Center and Research Institute, Tampa, FL,<sup>3<\/sup>Phenome Health, Seattle, WA,<sup>4<\/sup>TwinStrand Biosciences, Seattle, WA","CSlideId":"","ControlKey":"9980712d-c146-454d-80f6-964237ebc4b2","ControlNumber":"2268","DisclosureBlock":"&nbsp;<b>M. Yang, <\/b> None..<br><b>M. J. Schell, <\/b> None..<br><b>L. Pflieger, <\/b> None.&nbsp;<br><b>J. Salk, <\/b> <br><b>TwinStrand Biosciences<\/b> Employment.<br><b>T. J. Yeatman, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4150","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"16","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4343","PresenterBiography":null,"PresenterDisplayName":"Mingli Yang, PhD","PresenterKey":"d566b934-2166-44ea-ae6b-e2a7b024fcc2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4343. Development of an <i>APC<\/i> and <i>TP53<\/i>-based duplex sequencing assay to positively predict colorectal cancer response to EGFR inhibitors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Development of an <i>APC<\/i> and <i>TP53<\/i>-based duplex sequencing assay to positively predict colorectal cancer response to EGFR inhibitors","Topics":null,"cSlideId":""},{"Abstract":"<b>Background:<\/b> Gastric adenocarcinoma (GAC) is heterogeneous lethal disease in genomic and clinical level. Although the clinical relevance of genomic and molecular subtypes of GAC has been demonstrated, their translation to the clinic has been hindered by discrepancies in classification methods. We aim to examine a consensus of genomic subtypes and correlate them with clinical outcomes.<br \/><b>Method:<\/b> We collected genomic data from 2527 GAC tumors and divided the data into discovery (n = 1427) and validation sets (n = 1100). By integrating 8 previously established genomic subtype algorithms, we identified 6 clinically and molecularly distinct genomic consensus subtypes (CGSs) in discovery set. For validation of clinical significance of new subtypes, we constructed GAC predictor of integrated consensus subtype with 120 genes (GPICS120) and applied it to validation data set. In systematic analysis of genomic and proteomic data, we estimated potential response rate of each subtype to standard and experimental treatments such as radiation therapy, target therapy, and immunotherapy and further validated their functional significance in cell line models.<br \/><b>Results:<\/b> Among identified 6 subtypes. CGS1 is characterized by poorest prognosis, very high stem cell characteristics, and high IGF1 expression, but low genomic alterations. CGS2 showed canonical epithelial gene expression patterns. CGS3 and CGS4 are characterized by high copy number alterations and low immune activity. However, CGS3 and CGS4 are different in high HER2 activation (CGS3) and SALL4 and KRAS activation (CSG4). CGS5 has highest mutation burden and moderately high immune activity that is characteristics of MSI-high tumors. Most of CGS6 tumors are EBV-positive and shows extremely high methylation and high immune activity. Most interestingly, CSG1 is most responsive to immunotherapy while CGS3 is significantly associated with benefit of chemoradiation therapy due to high basal level ferroptosis. In addition, we also identified potential therapeutic targets for each subtype.<br \/><b>Conclusion:<\/b> Consensus subtype is robust classification system and can be the basis for pre-clinical investigation of subtype-based targeted interventions and future clinical trials.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Gastric cancer,Consensus subtypes,Clinical subtypes,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Yun Seong Jeong<\/b><sup>1<\/sup>, Young-Gyu Eun<sup>2<\/sup>, Sung Hwan Lee<sup>3<\/sup>, Sang-Hee Kang<sup>4<\/sup>, Sun Young Yim<sup>5<\/sup>, Eui Hyun Kim<sup>6<\/sup>, Joo Kyung Noh<sup>2<\/sup>, Bo Hwa Sohn<sup>1<\/sup>, Ju-Seog Lee<sup>1<\/sup><br><br\/><sup>1<\/sup>UT MD Anderson Cancer Center, Houston, TX,<sup>2<\/sup>Kyung Hee University, Seoul, Korea, Republic of,<sup>3<\/sup>CHA Bundang Medical Center, Seongnam, Korea, Republic of,<sup>4<\/sup>Korea University Guro Hospital, Seoulg, Korea, Republic of,<sup>5<\/sup>Korea University College of Medicine, Seoul, Korea, Republic of,<sup>6<\/sup>Yonsei University College of Medicine, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"7276c9e4-d41c-41ca-9e79-98f011a3746b","ControlNumber":"4945","DisclosureBlock":"&nbsp;<b>Y. Jeong, <\/b> None..<br><b>Y. Eun, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>S. Kang, <\/b> None..<br><b>S. Yim, <\/b> None..<br><b>E. Kim, <\/b> None..<br><b>J. Noh, <\/b> None..<br><b>B. Sohn, <\/b> None..<br><b>J. Lee, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4151","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"17","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4344","PresenterBiography":null,"PresenterDisplayName":"Yun Seong Jeong, PhD","PresenterKey":"0dfeb1fe-94d1-4a41-b224-be9e035f10d3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4344. Consensus genomic subtypes of gastric adenocarcinoma and their therapeutic implication","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Consensus genomic subtypes of gastric adenocarcinoma and their therapeutic implication","Topics":null,"cSlideId":""},{"Abstract":"While most patients with metastatic prostatic adenocarcinoma respond initially, nearly all develop resistance to multiple lines of androgen deprivation therapies. This is related to overexpression of the androgen receptor (AR), which is frequently driven by AR amplification. In some patients, increased AR renders tumor cells sensitive to high dose androgens which paradoxically inhibits their growth. Bipolar Androgen Therapy (BAT) was introduced in which patients with castration resistant prostate cancer (CRPC) are treated intermittently with high dose testosterone. This produces biochemical and objective responses, and may re-sensitize prostate cancer to subsequent second generation AR inhibitors. This study utilizes samples from a recently performed clinical trial for patients with CRPC that included sequential biopsies of soft tissue metastases before BAT and after 3 cycles of BAT and before patients were treated with nivolumab.Tumor cells were present in FFPE blocks for both the pretreatment and C4D1 time points for 24 of the patients. These FFPE samples were stained using a recently validated iterative multiplex IHC assay containing 6 antibodies including: CD3 (T cells), CD4 (Helper T Cells), CD8 (Cytotoxic T Cells), PD1 (T Cell Checkpoint), FOXP3 (T-Reg cells), and Keratin 8 (epithelial cell marker). Biopsy slides were scanned after each round of staining and whole slide scans were imported into the HALO image analysis where they underwent color deconvolution, image registration and fusion. Regions of tumor were demarcated manually, and computerized automated image analysis was used to determine cell densities for 8 cell phenotypes (total CD3+, CD3+CD4+, CD3+CD8+, CD3+CD4+Foxp3+, CD3+CD4+PD1+, CD3+CD8+PD1+, CD3+CD4+PD1-, CD3+CD8+PD1-). There was a higher density of CD3+CD8+PD1+ cells in the pretreatment biopsies of men who responded (R) (to BAT) as compared with those who did not respond (NR)( p=0.015 Wilcoxon rank-sum test; mean 92.7 [R] vs 13.9 [NR] ). The difference in R vs. NR was less and not significant in the CD3+CD8+PD1- population. There was a trend towards a higher density of CD3+CD4+PD1+ cells in the pretreatment samples in responders, but less so in the CD3+CD4+PD1- population. In the C4D1 biopsies, only CD3+ total cells were significantly higher in the R vs. NR (P=0.02), but the other phenotypes were not. We conclude that increased density of CD3+C8+PD1+, but not CD3+CD8+PD1- cells was present in pre-treatment biopsies in responders as compared with non-responders to BAT. These results indicate that men who are likely to respond to high dose testosterone treatment harbor tumors that are immunologically distinct prior to treatment than those men unlikely to respond. Additional spatial analysis and comparisons with RNAseq data will be presented.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Prostate cancer,Molecular diagnosis,Hormone receptors,Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Carolina Gomes Alexandre<\/b><sup>1<\/sup>, Jessica Hicks<sup>1<\/sup>, Tracy Jones<sup>2<\/sup>, John T Isaacs<sup>1<\/sup>, Kiara Bowers<sup>1<\/sup>, Alyza Skist<sup>1<\/sup>, Laura Sena<sup>1<\/sup>, Jennifer Meyers<sup>2<\/sup>, Emmanuel Antonarakis<sup>1<\/sup>, David Sanin<sup>1<\/sup>, Hanfei Qi<sup>1<\/sup>, Samuel Denmeade<sup>1<\/sup>, Mark Markowski<sup>1<\/sup>, Srinivasan Yegnasubramanian<sup>1<\/sup>, Angelo De Marzo<sup>1<\/sup><br><br\/><sup>1<\/sup>Johns Hopkins University School of Medicine, Baltimore, MD,<sup>2<\/sup>Pathology, Johns Hopkins University School of Medicine, Baltimore, MD","CSlideId":"","ControlKey":"40f316ab-2e22-49ce-b430-a82e29c918eb","ControlNumber":"7448","DisclosureBlock":"&nbsp;<b>C. Gomes Alexandre, <\/b> None..<br><b>J. Hicks, <\/b> None..<br><b>T. Jones, <\/b> None..<br><b>J. T Isaacs, <\/b> None..<br><b>K. Bowers, <\/b> None..<br><b>A. Skist, <\/b> None..<br><b>L. Sena, <\/b> None..<br><b>J. Meyers, <\/b> None..<br><b>E. Antonarakis, <\/b> None..<br><b>D. Sanin, <\/b> None..<br><b>H. Qi, <\/b> None..<br><b>S. Denmeade, <\/b> None..<br><b>M. Markowski, <\/b> None..<br><b>S. Yegnasubramanian, <\/b> None..<br><b>A. De Marzo, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4152","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"18","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4345","PresenterBiography":null,"PresenterDisplayName":"Carolina Gomes Alexandre, MD","PresenterKey":"fe12daeb-33c7-46c1-ac3c-7c7f914103fc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4345. Molecular pathology studies reveal PD1+ CD8 T cell density correlates with response to supraphysiological testosterone treatment in pre-treatment biopsies and MYC mRNA and protein correlate with response after treatment","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Molecular pathology studies reveal PD1+ CD8 T cell density correlates with response to supraphysiological testosterone treatment in pre-treatment biopsies and MYC mRNA and protein correlate with response after treatment","Topics":null,"cSlideId":""},{"Abstract":"<b>Background: <\/b>Cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6is) in combination with endocrine therapy (ET) have become the mainstay treatment for patients with hormone receptor (ER)-positive, HER2-negative metastatic breast cancer (BC). However, one-third of patients do not respond to the treatment (intrinsic resistance), leading to early tumor progression and treatment failure, and most patients eventually acquire resistance to therapy. The exact mechanisms of resistance to CDK4\/6i are yet to be elucidated, and due to subsequent early (intrinsic) or late progression on CDK4\/6i, long-term cures are not achieved.<br \/><b>Methods<\/b>: Transcriptomic profiles of BC cell lines that were sensitive or resistant to approved CDK4\/6i, independent of subtype, were downloaded from the Cancer Cell Line Encyclopedia database. Bioinformatics analysis was performed by integrated Differential Expression and Pathway (iDEP) workflow. In parallel, transcriptomic profiles of metastatic biopsies from pre-CDK4\/6i-treated BC patients (n = 54) were generated using RNA-Access technology. Key common biomarkers identified from the BC cell lines and patient tumor samples were validated by immunohistochemistry in formalin-fixed paraffin-embedded (FFPE) metastatic specimens from 73 patients prior to CDK4\/6i therapy.<br \/><b>Results<\/b>: Transcriptomic profile comparisons of BC cell lines (n = 35) that were sensitive versus resistant to CDK4\/6is identified Trefoil Factor 1 and 3 (TFF1 and TFF3) secretory proteins as top predictors of response. Correlation analysis showed a strong negative correlation between TFF1 and TFF3 levels to IC50 values of palbociclib and abemaciclib. Knockdown of TFF3 in CDK4\/6i-sensitive BT20 cells with shRNA induced drug resistance in the cells. Transcriptomic data from 54 BC patients pre-treated with CDK4\/6i showed the expression levels of TFF1 and TFF1\/3 receptors (CCR4 and CCR7) were significantly increased in patients who developed late progression (&#62; 6 months) compared to early progressors (&#60; 3 months). In addition, IHC analysis of TFF1 and TFF3 expressions in 73 pre-treated BC patient samples showed significantly higher protein expression levels in late progressors than in early progressors.<br \/><b>Conclusions<\/b>: Our results identified and validated the common biomarkers, TFF1 and TFF3, as predictors of CDK4\/6i response efficacy in ER-positive, HER2-negative BC patients. These findings provide a predictive tool capable of selecting <i>de novo<\/i> metastatic BC patients who will have the greatest benefit from the combination of CDK4\/6i with endocrine treatment. Furthermore, our discovery of biomarkers in early versus late progression on CDK4\/6i therapy will enable new therapeutic avenues and provide the rationale for future large-scale clinical trials.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"CDK4\/6 inhibitors,Biomarkers,Drug sensitivity,Drug resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Linjie Luo<\/b><sup>1<\/sup>, Yan Wang<sup>2<\/sup>, Sophia Mastoraki<sup>2<\/sup>, Akshara Singareeka Raghavendra<sup>3<\/sup>, Juliana Navarro-Yepes<sup>2<\/sup>, Nicole  M.  Kettner<sup>1<\/sup>, Serena Kim<sup>4<\/sup>, Debasish Tripathy<sup>5<\/sup>, Kelly Hunt<sup>6<\/sup>, Khandan Keyomarsi<sup>1<\/sup><br><br\/><sup>1<\/sup>Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,<sup>2<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX,<sup>3<\/sup>Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,<sup>4<\/sup>2School of Social Sciences, Rice University, Houston, TX,<sup>5<\/sup>Breast Cancer Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,<sup>6<\/sup>Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"245a6abb-941b-4b50-b2d0-b2122b65f9f9","ControlNumber":"6916","DisclosureBlock":"&nbsp;<b>L. Luo, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>S. Mastoraki, <\/b> None..<br><b>A. Singareeka Raghavendra, <\/b> None..<br><b>J. Navarro-Yepes, <\/b> None.&nbsp;<br><b>N. M. Kettner, <\/b> <br><b>Novartis<\/b> Grant\/Contract.<br><b>S. Kim, <\/b> None..<br><b>D. Tripathy, <\/b> None..<br><b>K. Hunt, <\/b> None..<br><b>K. Keyomarsi, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4153","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"19","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4346","PresenterBiography":null,"PresenterDisplayName":"Linjie Luo, MD;PhD","PresenterKey":"0101ae00-247e-4177-ad1a-3a8348a71a9d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4346. TFF1 and TFF3 predict response to CDK4\/6 inhibitors in breast cancer patients","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"TFF1 and TFF3 predict response to CDK4\/6 inhibitors in breast cancer patients","Topics":null,"cSlideId":""},{"Abstract":"Precision cancer therapy has the potential to revolutionize treatment outcome. While genomic analysis has become central to cancer personalized medicine, recent studies have not shown that it drastically improves the patient&#8217;s survival as compared to standard drug selection. Additionally, genomic mutations may suggest several treatment protocols without elucidating which approach will yield the best clinical response. To advance cancer precision guidance, we have developed cResponse, a combined genomic-functional drug sensitivity platform to determine individualized patient treatment regimens. Fresh patient cancer samples are taken by biopsy or resection and sectioned into 250uM slices which when cultured in cResponse platform demonstrate similar architecture and tissue proliferation to those found in vivo. An initial clinical study showed that cResponse can preserve human cancer tissue in 3D culture together with its microenvironment, including endothelial and immune cells, at a high viability (&#62;90%) with continued cell division for more than 7 days. On a cohort of 34 patients treated with neoadjuvant therapy or systemic therapy for metastatic disease, the assay was able to predict patient response to drug treatment with a sensitivity of 96% and a specificity of 77.7%. To further validate the capacity of the cResponse platform to predict patient response to cancer therapy, a follow up pivotal clinical study was established at 7 major cancer centers located in the UK with the goal of recruiting a total of 170 patients to provide a large statistical validation of the previous results. Here we report on the outcome of the first 50 patients recruited to the pivotal trial and describe the predictive results correlated to patient response.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Biomarkers,Tumor microenvironment,Precision medicine,Ex vivo,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Seth Salpeter<\/b><sup>1<\/sup>, Vered Bar<sup>1<\/sup>, Guy Neev<sup>1<\/sup>, Adi Zundelevich<sup>1<\/sup>, Gil Rosen<sup>1<\/sup>, Sandra Hanks<sup>2<\/sup>, Naoise Costelloe<sup>3<\/sup>, Jonathan Krell<sup>4<\/sup>, Ravid Straussman<sup>5<\/sup><br><br\/><sup>1<\/sup>Curesponse Ltd, Rehovot, Israel,<sup>2<\/sup>Curesponse UK Ltd, Sutton, United Kingdom,<sup>3<\/sup>Curesponse UK, Sutton, United Kingdom,<sup>4<\/sup>Imperial College, London, United Kingdom,<sup>5<\/sup>Weizmann Institute, Rehovot, Israel","CSlideId":"","ControlKey":"d6f001e1-624f-4bd8-bd38-c1c1056227f1","ControlNumber":"6843","DisclosureBlock":"<b>&nbsp;S. Salpeter, <\/b> <br><b>Curesponse<\/b> Employment. <br><b>V. Bar, <\/b> <br><b>Curesponse<\/b> Employment. <br><b>G. Neev, <\/b> <br><b>Curesponse<\/b> Employment. <br><b>A. Zundelevich, <\/b> <br><b>Curesponse<\/b> Employment. <br><b>G. Rosen, <\/b> <br><b>Curesponse<\/b> Employment. <br><b>S. Hanks, <\/b> <br><b>Curesponse<\/b> Employment. <br><b>N. Costelloe, <\/b> <br><b>curesponse<\/b> Employment.<br><b>J. Krell, <\/b> None.&nbsp;<br><b>R. Straussman, <\/b> <br><b>Curesponse<\/b> Stock.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4154","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"20","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4347","PresenterBiography":null,"PresenterDisplayName":"Seth Salpeter","PresenterKey":"23ef4a64-f69e-4d2f-abf0-fba931d89779","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4347. A pivotal clinical trial of cResponse, a functional assay for cancer precision medicine","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A pivotal clinical trial of cResponse, a functional assay for cancer precision medicine","Topics":null,"cSlideId":""},{"Abstract":"Background: We previously reported the development and validation of an integrative Immunotherapy Response Score (IRS) algorithm, which integrates tumor mutation burden (TMB) and quantitative gene expression of PD-L1, PD-1, ADAM12 and TOP2A, to predict PD-1 or PD-L1 (together PD-[L]1) monotherapy (mono) benefit across solid tumors from routine formalin fixed paraffin embedded samples. Herein, we evaluated IRS performance for predicting pembrolizumab (pembro) mono benefit in a second, independent validation cohort.<br \/>Methods: We identified patients from an ongoing observational trial (NCT03061305) integrating molecular profiling with real world treatment data who were 1) treated with systemic pembro mono, 2) not included in the original IRS cohort, and 3) had valid molecular profiling data to generate IRS. IRS status (IRS-High [H] vs. -Low [L] by the previously validated threshold; -H with increased benefit) association with pembro real world progression free survival (rwPFS) by time-to-next therapy was determined by Cox proportional hazard modeling (adjusting for age, gender, line of systemic therapy, and PD-(L)1 mono indicated (microsatellite instable high [MSI-H], TMB-H, or approved tumor type) vs. not indicated. The predictive nature of the IRS biomarker was assessed in the subset of &#62;= 2nd line patients through a case cross-over analysis (pembro rwPFS vs. immediately preceding therapy line rwPFS) as assessed by likelihood ratio test (LRT).<br \/>Results: Of the 176 patients in this independent validation cohort (from 25 tumor types), 78 (44%) patients were IRS-H, while 40 (23%) were TMB-H. Pembro mono rwPFS was significantly longer in IRS-H vs. IRS-L patients (median rwPFS 18.7 vs. 6.4 months, adjusted hazard ratio [aHR] 0.46, p=0.007), while PD-(L)1 mono indicated status was not associated with pembro mono rwPFS (indicated vs. not indicated aHR 1.47, p=0.26). In the case cross-over analysis of 55 (31%) patients treated with systemic therapy prior to pembro mono, pembro rwPFS was significantly longer than preceding therapy in IRS-H patients (median 18.7 vs. 5.5 months) but not IRS-L patients (median 4.9 vs. 5.4 months); the LRT for interaction between IRS status and pembro\/prior therapy was significant (p=0.046); results in the TMB-L\/non-MSI-H subset (n=45) of patients was similar (LRT p=0.025).<br \/>Conclusion: These results confirm the pan-solid tumor PD-(L)1 monotherapy predictive nature of the IRS biomarker.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Immunotherapy,Biomarkers,Pembrolizumab,Personalized medicine,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Benjamin  J.  Bulen<\/b><sup><\/sup>, Nickolay  A.  Khazanov<sup><\/sup>, Laura  E.  Lamb<sup><\/sup>, Daniel  H.  Hovelson<sup><\/sup>, Kat Kwiatkowski<sup><\/sup>, D. Bryan Johnson<sup><\/sup>, Daniel  R.  Rhodes<sup><\/sup>, Scott  A.  Tomlins<sup><\/sup><br><br\/>Strata Oncology, Ann Arbor, MI","CSlideId":"","ControlKey":"8e025037-c25d-4515-9288-c837d129d87a","ControlNumber":"6532","DisclosureBlock":"<b>&nbsp;B. J. Bulen, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock Option. <br><b>N. A. Khazanov, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock Option, Patent. <br><b>L. E. Lamb, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock Option. <br><b>D. H. Hovelson, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock Option. <br><b>K. Kwiatkowski, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock Option. <br><b>D. Johnson, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock Option, Patent. <br><b>D. R. Rhodes, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock, Stock Option, Patent. <br><b>Javelin Oncology<\/b> Stock, Stock Option. <br><b>S. A. Tomlins, <\/b> <br><b>Strata Oncology<\/b> Employment, Stock, Stock Option, Patent. <br><b>Javelin Oncology<\/b> Stock Option. <br><b>Astellas\/Medivation<\/b> Grant\/Contract, Other, Consultant. <br><b>Janssen<\/b> Other, Consultant. <br><b>Prostate Cancer Foundation.<\/b> Travel.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4155","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"21","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4348","PresenterBiography":null,"PresenterDisplayName":"Benjamin Bulen, MS","PresenterKey":"95f639dd-19db-4542-abbc-2cc1635c904a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4348. Validation of an integrative pan-solid tumor predictor of pembrolizumab monotherapy benefit","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Validation of an integrative pan-solid tumor predictor of pembrolizumab monotherapy benefit","Topics":null,"cSlideId":""},{"Abstract":"Anti-tumoral T cell immunity is counterbalanced by several types of immunosuppressive cells such as Myeloid-Derived Suppressor Cells (MDSC). Circulating MDSC levels correlate with poor prognosis and metastatic progression of breast cancer patients. However, the value of MDSC in predicting chemotherapeutic treatment responses in the metastatic lesions is not clearly understood. We performed a prospective cohort clinical study to measure MDSC before and after chemotherapy in metastatic breast cancer patients (<i>N<\/i>=64). Multicolor flow cytometry was used to quantitate two major subtypes, i.e. monocytic (M-) and polymorphonuclear (PMN-) MDSC, and one additional subtype, C-C chemokine receptor 2 (CCR2)-positive M-MDSC in the fresh peripheral blood mononuclear cells. M-MDSC were defined as HLA-DR<sup>low\/-<\/sup>CD45<sup>+<\/sup>CD11b<sup>+<\/sup>CD15<sup>-<\/sup>CD14<sup>+ <\/sup>PBMC, and PMN-MDSC were defined as CD45<sup>+<\/sup>CD11b<sup>+<\/sup>CD33<sup>+<\/sup>CD15<sup>+ <\/sup>CD14<sup>- <\/sup>PBMC. PMN-MDSC and CCR2<sup>+<\/sup> M-MDSC, but not M-MDSC, were significantly increased after chemotherapy. Subsequently, we divided the patients by two groups (therapy-sensitive <i>vs<\/i>. -resistant groups) by treatment responses. Treatment-resistant patients had significantly increased CCR2<sup>+<\/sup> M-MDSC. Unsupervised clustering of patients based on MDSCs populations dichotomized patients PMN-MDSC high or M-MDSC high groups. M-MDSC high patients had increased bone and lymph node metastasis. In addition, CCR2<sup>+ <\/sup>M-MDSC levels correlated with the progression-free survival (<i>P<\/i>&#60;0.05). Altogether, our results showed that CCR2<sup>+ <\/sup>M-MDSC levels potentially predict the therapeutic responses in the metastatic lesions of breast cancer patients.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"MDSC,Breast cancer,Metastasis,Flow cytometry,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Ju Won Kim<sup>1<\/sup>, Jason  K.  Sa<sup>2<\/sup>, Seung Pil Jung<sup>3<\/sup>, Kyong Hwa Park<sup>1<\/sup>, <b>Serk In Park<\/b><sup>4<\/sup><br><br\/><sup>1<\/sup>Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea, Republic of,<sup>2<\/sup>Biomedical Sciences, Korea University College of Medicine, Seoul, Korea, Republic of,<sup>3<\/sup>Department of Surgery, Korea University Anam Hospital, Seoul, Korea, Republic of,<sup>4<\/sup>Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"1d59534e-5df7-4655-b536-ca46249a580a","ControlNumber":"6271","DisclosureBlock":"&nbsp;<b>J. Kim, <\/b> None..<br><b>J. K. Sa, <\/b> None..<br><b>S. Jung, <\/b> None..<br><b>K. Park, <\/b> None..<br><b>S. Park, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4156","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"22","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4349","PresenterBiography":null,"PresenterDisplayName":"Serk In Park, DDS;PhD","PresenterKey":"a7ab38f5-e2f8-46a6-ae2d-acccf7d88188","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4349. C-C chemokine receptor 2-positive monocytic myeloid-derived suppressor cells predicts chemotherapeutic responses of the metastatic lesions in breast cancer patients","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"C-C chemokine receptor 2-positive monocytic myeloid-derived suppressor cells predicts chemotherapeutic responses of the metastatic lesions in breast cancer patients","Topics":null,"cSlideId":""},{"Abstract":"We have developed a method to assess target expression changes following exposure of plucked hairs to chemotherapeutic agents and other potential therapeutics. Successful <i>ex vivo<\/i> responses provide proof of concept data prior to clinical studies. Plucked hair is a valuable surrogate biomarker tissue to monitor pharmacodynamic (PD) responses in a clinical trial. The collection of hairs is minimally invasive, simple and is amenable to frequent sampling. Since hairs are epithelial appendages, many signaling pathways active in other epithelial tissues, including cancers, are also present in hairs. Highly proliferative plucked human scalp hair can be utilized as a surrogate tissue to measure proliferation, phosphorylation and DNA damage responses after treatment. Furthermore, hairs are highly vascularized, suggesting that administered Test Articles may be delivered efficiently to the hair in a similar manner to other highly vascularized tissues, including many tumor types. Human plucked hair (either from the scalp or beard) was placed in maintenance media in the presence of conventional or targeted chemotherapeutic agents, known for their different mechanisms of action (e.g. Gemcitabine, Carboplatin, Tarceva), for a range of time points. Hairs were then fixed post-exposure and longitudinal sections immunohistochemically labelled for various markers including p-ERK1\/2, p-AKT, p-Chk1, g-H2AX, Ki67 and androgen receptor. Quantitative image analysis to measure the level of labelling was performed using an Aperio ScanScope. The relative number of positively labelled cell nuclei, or relative tissue area (depending on the labelling pattern of the target), of the hair outer root sheath labelled was analyzed, along with label intensity. In subsequent trial patients, formaldehyde fixed plucked hairs were returned to the lab, similarly sectioned, labelled and quantified. In addition, where antibody labelling is not possible or more detailed information on the modulation of a pathway may be useful, drug treated plucked hairs can be subjected to Next Generation Sequencing (NGS) gene expression analysis. The expected changes in labelling were observed. For example, Gemcitabine, which is linked to DNA polymerase inhibition, increased p-Chk1 labelling 4-fold after 4-8 hours and strongly induced p53 by 24 hours. Tarceva, an inhibitor of the EGF pathway, decreased levels of both p-ERK1\/2 and p-AKT 3-fold after only 10 minutes. The alkylating agent carboplatin increased g-H2AX labelling up to 12-fold after 24 hours. We have demonstrated that plucked hair is a valuable PD biomarker tissue for various chemotherapy agents. Proof of concept studies performed <i>ex vivo<\/i> can inform the design of clinical validation studies by indicating optimum markers and timepoints. Further, each hair is an independent unit thereby allowing independent replicate tissues (hairs) to be sampled.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Biomarkers,Immunohistochemistry,Therapeutics,Image analysis,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Greg Tudor<\/b><sup><\/sup>, Frida Ponthan<sup><\/sup>, Adam Boanas<sup><\/sup>, Aude-Marine Bonavita<sup><\/sup>, Catherine Booth<sup><\/sup><br><br\/>Epistem Ltd, Manchester, United Kingdom","CSlideId":"","ControlKey":"4c94c5dd-4d10-400f-a6e1-d00762778277","ControlNumber":"5983","DisclosureBlock":"&nbsp;<b>G. Tudor, <\/b> None..<br><b>F. Ponthan, <\/b> None..<br><b>A. Boanas, <\/b> None..<br><b>A. Bonavita, <\/b> None..<br><b>C. Booth, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4157","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"23","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4350","PresenterBiography":null,"PresenterDisplayName":"Greg Tudor","PresenterKey":"d3d1459a-6613-4b58-a478-47c4cbee4466","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4350. Pharmacodynamic biomarkers: Evaluation of oncology drug target engagement in human plucked scalp and beard hair","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pharmacodynamic biomarkers: Evaluation of oncology drug target engagement in human plucked scalp and beard hair","Topics":null,"cSlideId":""},{"Abstract":"Purpose: Oncogenic Kirsten rat sarcoma virus (KRAS) mutations are the most prevalent cancer mutations in all human tumors. Also, genotyping the KRAS gene has become increasingly important with the emergence of new evidence highlighting differences in downstream signaling pathways, tumor microenvironment composition, treatment responses and prognoses linked to specific single nucleotide polymorphisms (SNPs) in the G12 or G13 codons. FDA approval of G12C-specific anti-KRAS drugs highlights the importance of the development of reliable SNP assays to interrogate the mutation status in a tumor sample. Currently available genotyping assays are based on NGS, PCR, or ddPCR. These methods can be time-consuming, costly, suffer from amplification bias, or require follow-up testing or bioinformatics skills to analyze. Building on Meso Scale Discovery&#8217;s (MSD) existing technology, we aimed to develop a method for the identification of eight KRAS SNPs located on the G12-G13 codons in a single reaction.<br \/>Methods: Ten-spot, 96-well N-PLEX plates were used for the study. SNP-specific upstream probes carrying unique 5&#8242; leader sequences complementary to spot-specific captures on the N-PLEX plates were designed for eight KRAS genotypes (WT, G12R, G12C, G12S, G12A, G12D, G12V, G13D). Locus-specific downstream probes were 5&#8217; phosphorylated for ligation and 3&#8217; biotinylated for detection. Synthetic DNA targets were used as assay calibrators, and commercially available FFPE reference samples were tested for validation. DNA (10 ng) was PCR amplified with primers flanking the KRAS mutation sites. A multiplexed mixture of upstream and downstream probes was hybridized to the amplicons, and 30 cycles of ligation was performed using DNA ligase in a thermal cycler. Samples were subsequently hybridized to spot-specific capture oligonucleotides on the surface of the assay plates and detected with SULFO-TAG labeled streptavidin. Electrochemiluminescence readout was collected on an MSD imager.<br \/>Results: Optimization of probe concentrations and ligation temperature was performed to maximize signal-to-background ratios and assay specificity. Spike recovery experiments using artificial target DNA showed successful identification of KRAS mutant genotypes at spike levels as low as 0.1% over wild-type background. Validation experiments with gDNA extracted from FFPE reference samples confirmed that the multiplex SNP assay can accurately differentiate eight KRAS genotypes in samples with &#62;0.4% tumor burden.<br \/>Conclusion: These data highlight a novel approach to simultaneously identify eight KRAS genotypes from 10 ng of DNA input in a single reaction within 4-5 hours. The assay is capable of identifying double mutants and can provide a semiquantitative assessment of tumor burden without the need for follow-up testing.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"KRAS,SNP,Assay development,Tumor mutational burden,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Annamaria Szabolcs<\/b><sup>1<\/sup>, Timothy J. Break<sup>1<\/sup>, Isaac  H.  Shin<sup>1<\/sup>, Seth  B.  Harkins<sup>1<\/sup>, Jacob  N.  Wohlstadter<sup>2<\/sup><br><br\/><sup>1<\/sup>Assay Development, Meso Scale Discovery, Rockville, MD,<sup>2<\/sup>Meso Scale Discovery, Rockville, MD","CSlideId":"","ControlKey":"2824d72e-56fd-473d-8e5c-e667b7aa580d","ControlNumber":"228","DisclosureBlock":"&nbsp;<b>A. Szabolcs, <\/b> None..<br><b>T. J. Break, <\/b> None..<br><b>I. H. Shin, <\/b> None..<br><b>S. B. Harkins, <\/b> None..<br><b>J. N. Wohlstadter, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4158","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"24","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4351","PresenterBiography":null,"PresenterDisplayName":"Annamaria Szabolcs, MD;PhD","PresenterKey":"7937da28-8b42-40a0-97e9-adf898da4255","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4351. Multiplex detection of G12\/G13 KRAS mutations with an electrochemiluminescent hybridization assay","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Multiplex detection of G12\/G13 KRAS mutations with an electrochemiluminescent hybridization assay","Topics":null,"cSlideId":""},{"Abstract":"Extracellular vesicles (EV) play an important role in melanoma progression but their potential as clinical biomarkers has yet to be realized. EVs can be found in most liquid biopsies (e.g., blood, urine, CSF) and exosomes are the most prominent subcategory of EVs. Exosomes are 50-200 nm lipid-bilayer enclosed particles secreted by all body cells, including tumor cells, and serve as mediators of metastasis formation and typically contain several classes of bioactive molecules such as RNA, proteins, lipids, and metabolites.<br \/>Blood and its liquid components plasma\/serum are the most frequently used matrix for biomarker discovery due to the ease of collection. However, most proteomic platforms for plasma\/serum profiling are unable to profile EV proteins due to the high dynamic range of protein concentrations in EV preparations. This is due to 1) EV isolation methods that vary in their potential to separate EVs from free proteins, and 2) the presence of a natural corona of high-abundant blood proteins attached to the EV surface. To tackle this challenge, we developed SEC-DIA-MS an integrated workflow combining size-exclusion chromatography, EV concentration, and optimized mass spectrometry to enable deep profiling of the proteome content of the enriched vesicles.<br \/>From 200 &#181;l of plasma or serum from a test melanoma patient cohort (6 patients and 3 matched controls), we quantified 2,242 exosome-associated proteins, achieving a 2.5-fold increase in depth compared to previous melanoma studies. To gain a better understanding of the exosome enrichment efficiency, we extensively characterized the plasma\/serum proteome by analyzing native, depleted, and EV-enriched blood from the same donors. We successfully validated well-known exosome markers such as CD9, CD63, CD81, PDCD6IP, and TSG101, and found that EV samples are significantly enriched in intact membrane proteins and those related to T cell biology, further underlining the uniqueness of the EV proteome composition. We further assessed the differences between plasma and serum EVs and suggest the use of plasma samples for future studies due to better separation of healthy and melanoma samples. Furthermore, known melanoma markers such as MCAM, TNC, and TGFBI were upregulated in melanoma plasma-derived EV but not depleted plasma samples, highlighting the specific information contained in EVs.<br \/>Taken together, we demonstrated the applicability and potential of an EV-based proteomic workflow for biomarker discovery in plasma and serum. The ease of automating and scaling up such an approach enables a broader application to other indications and biological matrices.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Melanoma\/skin cancers,Exosomes,Biomarkers,Proteomics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Evelyn Lattmann<sup>1<\/sup>, Luca Räss<sup>2<\/sup>, Marco Tognetti<sup>2<\/sup>, Julia Martinez Gomez<sup>1<\/sup>, Valérie Lapaire<sup>1<\/sup>, Roland Bruderer<sup>2<\/sup>, Lukas Reiter<sup>2<\/sup>, <b>Yuehan Feng<\/b><sup>2<\/sup>, Lars  M.  Steinmetz<sup>3<\/sup>, Mitchell  P.  Levesque<sup>1<\/sup><br><br\/><sup>1<\/sup>Department of Dermatology, University of Zurich, University Hospital Zurich, Schlieren, Switzerland,<sup>2<\/sup>Biognosys AG, Schlieren, Switzerland,<sup>3<\/sup>Department of Genetics, Stanford University School of Medicine, Palo Alto, CA","CSlideId":"","ControlKey":"f347fa45-080c-4768-b233-ebcd8e223254","ControlNumber":"3130","DisclosureBlock":"&nbsp;<b>E. Lattmann, <\/b> None..<br><b>L. Räss, <\/b> None..<br><b>M. Tognetti, <\/b> None..<br><b>J. Martinez Gomez, <\/b> None..<br><b>V. Lapaire, <\/b> None..<br><b>R. Bruderer, <\/b> None..<br><b>L. Reiter, <\/b> None..<br><b>Y. Feng, <\/b> None..<br><b>L. M. Steinmetz, <\/b> None..<br><b>M. P. Levesque, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4159","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"25","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4352","PresenterBiography":null,"PresenterDisplayName":"Yuehan Feng, PhD","PresenterKey":"7307bad2-eacb-448b-9ce8-96a5ea8dcbd1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4352. Leveraging deep proteome profiling of plasma- and serum-derived extracellular vesicles for melanoma biomarker discovery and disease dissection","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Leveraging deep proteome profiling of plasma- and serum-derived extracellular vesicles for melanoma biomarker discovery and disease dissection","Topics":null,"cSlideId":""},{"Abstract":"Triple-Negative Breast Cancer (TNBC) is an aggressive breast cancer subset, which lacks expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor-2. This subset of breast cancer disproportionately affects Black and African American women and improving TNBC treatment options is vital to reducing breast cancer mortality. The novel antibody-drug conjugate, Sacitizumab Govetican (SG), which targets TROP2 at the cell surface, has shown promising clinical results from the NeoSTAR trial (NCT04230109), a phase II study evaluating neoadjuvant SG therapy in a localized TNBC setting. As part of the NeoSTAR clinical trial, we have collected and processed pre- and post- SG treatment patient samples, with the aim of understanding response to this monotherapy. Herein, we identify biomarkers of response and resistance to SG monotherapy through the use of single cell RNA sequencing of matched pre- and post-treatment patient biopsies combined with exome sequencing these patient samples. Pre-treatment core needle biopsy samples, and if applicable, post-treatment residual disease biopsies were dissociated into single cell suspensions and subjected to single cell RNA sequencing. Additionally, fixed patient tissue samples were processed accordingly for exome sequencing analyses. Overall, we analyzed over 144,000 cells from 37 total scRNA seq libraries with an average of 3800 cells per biopsy sample, demonstrating the feasibility of this method. From these analyses, we observed several cell-type differences between patients who achieved a pathological complete response (pCR) and patients who had residual disease (RD). Specifically, our data shows that tumor infiltrating lymphocytes are a potential prognostic biomarker of response to SG. Furthermore, we detected alterations in among stromal and immune cell subsets, among non-responders, indicating that these cell types maybe indicative of SG resistance. Taken together, we outline biomarkers of response to SG treatment for an improved understanding of resistance mechanisms in the neoadjuvant setting to improve TNBC outcomes among patients.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Triple-negative breast cancer (TNBC),Antibody-drug conjugate (ADC),Single cell,Trop-2,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Nicole Peiris<\/b><sup>1<\/sup>, Simona Cristea<sup>2<\/sup>, Mengran Zhang<sup>2<\/sup>, Siang Koh<sup>1<\/sup>, James Coates<sup>1<\/sup>, Ilze Smidt<sup>1<\/sup>, Veerle Bossuyt<sup>1<\/sup>, Laura Spring<sup>1<\/sup>, Aditya Bardia<sup>1<\/sup>, Leif Ellisen<sup>1<\/sup><br><br\/><sup>1<\/sup>Harvard Medical School, Massachusetts General Hospital, Boston, MA,<sup>2<\/sup>Harvard Medical School, Dana Farber Cancer Institute, Boston, MA","CSlideId":"","ControlKey":"bebb122b-efaa-437b-b814-eff91f238ead","ControlNumber":"5333","DisclosureBlock":"&nbsp;<b>N. Peiris, <\/b> None..<br><b>S. Cristea, <\/b> None..<br><b>M. Zhang, <\/b> None..<br><b>S. Koh, <\/b> None..<br><b>J. Coates, <\/b> None..<br><b>I. Smidt, <\/b> None..<br><b>V. Bossuyt, <\/b> None..<br><b>L. Spring, <\/b> None.&nbsp;<br><b>A. Bardia, <\/b> <br><b>Sanofi<\/b> Grant\/Contract. <br><b>Radius Health<\/b> Grant\/Contract. <br><b>Mersana<\/b> Grant\/Contract. <br><b>Innocrin<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Taiho Pharma<\/b> Other, Advisory board. <br><b>Spectrum Pharma<\/b> Other, Advisory board. <br><b>Biotheranostics<\/b> Grant\/Contract.<br><b>L. Ellisen, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4160","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"26","PosterboardNumber":"28","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4353","PresenterBiography":null,"PresenterDisplayName":"Nicole Peiris, MS,PhD","PresenterKey":"323f1c88-1f22-4b03-a5e0-8e0b1c88d825","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4353. Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacitizumab Govetican in localized TNBC","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacitizumab Govetican in localized TNBC","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2-) breast cancer is the most common type of breast cancer. Patients with HR+\/HER2- metastatic breast cancer (mBC) often become resistant to aromatase inhibitors commonly used in endocrine therapy (ET). Estrogen receptor (<i>ESR1<\/i>) ligand binding domain mutations are frequently detected in HR+ mBC and have been reported to be associated with ET resistance, noting up to 60% patients with mBC will develop resistance to treatment via acquired resistance in ESR1. Recent studies have shown that monitoring of <i>ESR1<\/i> mutations in plasma may serve as a predictive biomarker of acquired resistance to ET, showcasing a strong need for sensitive nucleic acid-based assays. We describe a comprehensive methodology for targeted clinical RT-qPCR monitoring of <i>ESR1<\/i> mutations in plasma that utilizes both exosomal nucleic acids and cfDNA to report multiple mutations, provide a streamlined workflow, and accommodate a range of inputs from clinically relevant samples.<br \/>Methods: Exosomal nucleic acids (exosomal DNA and RNA) and circulating cell-free DNA (cfDNA) were co-isolated using the ExoLution Plus Isolation Kit (Exosome Diagnostics). RT-qPCR-based target enrichment was performed using modified QuantideX reagents (Asuragen) and mutations were confirmed on the QuantStudio qPCR Platform (ThermoFisher). Bioinformatic analyses were conducted using custom software.<br \/>Results: We developed novel technologies and tested greater than samples across key ET resistance mutations, utilizing contrived samples as needed due to availability. Preliminary studies demonstrated that ESR1 exosomal RNA + cfDNA ranged from approximately 9,500 copies to 64,000 copies in a set of 2mL female presumed normal plasma samples; these results suggest that even 2mL plasma could provide sufficient exosomal RNA\/DNA + cfDNA for mutation detection at variant frequencies less than or equal to 0.01%. The <i>ESR1<\/i> RT-qPCR showed greater than 90% analytical sensitivity (at less than or equal to 1% mutant allele frequency) and greater than90% analytical specificity. Further, the technology detected less than 10 mutant copies for most tested mutants, showing an LOD of at least 0.1% (5 mutant copies in a background of 5,000 WT copies).<br \/>Conclusion: A fast, efficient, and sensitive <i>ESR1<\/i> RT-qPCR panel approach was developed and evaluated, demonstrating the reliable and specific detection of rare variants in liquid biopsy specimens. Importantly, this prototype technology has potential to address several challenges associated with mutation monitoring in liquid biopsies by expanding detection of mutant analytes (exosomal RNA and DNA), improving analytical sensitivity (novel reagents and software), and increasing accessibility (qPCR instrument install base).","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-03 Early detection biomarkers,,"},{"Key":"Keywords","Value":"Estrogen receptor,Liquid biopsies,Mutation detection,Breast cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Sarah Statt<\/b><sup>1<\/sup>, Julie Thibert<sup>1<\/sup>, Kurt Franzen<sup>2<\/sup>, Aquiles Sanchez<sup>2<\/sup>, Liangjing Chen<sup>1<\/sup>, Megan Yociss<sup>1<\/sup>, Elliot Hallmark<sup>1<\/sup>, Melissa Church<sup>1<\/sup>, Stela Filipovic-Sadic<sup>1<\/sup>, Gary Latham<sup>1<\/sup>, Johan Skog<sup>2<\/sup><br><br\/><sup>1<\/sup>Asuragen, a bio-techne brand, Austin, TX,<sup>2<\/sup>ExosomeDx, a bio-techne brand, Austin, TX","CSlideId":"","ControlKey":"8bc60ba1-2d1c-4cf8-a928-887946abff4d","ControlNumber":"6925","DisclosureBlock":"<b>&nbsp;S. Statt, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>J. Thibert, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>K. Franzen, <\/b> <br><b>ExosomeDx, a bio-techne brand<\/b> Employment. <br><b>A. Sanchez, <\/b> <br><b>ExosomeDx, a bio-techne brand<\/b> Employment. <br><b>L. Chen, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>M. Yociss, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>E. Hallmark, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>M. Church, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>S. Filipovic-Sadic, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>G. Latham, <\/b> <br><b>Asuragen, a bio-techne brand<\/b> Employment. <br><b>J. Skog, <\/b> <br><b>ExosomeDx, a bio-techne brand<\/b> Employment.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"4228","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"27","PosterboardNumber":"29","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4354","PresenterBiography":null,"PresenterDisplayName":"Sarah Statt, PhD","PresenterKey":"49b47ff1-7f2a-49d3-9c2e-13034431e314","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4354. An exosome-based <i>ESR1<\/i> monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at &#8804;0.1% frequency in liquid biopsy samples","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"An exosome-based <i>ESR1<\/i> monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at &#8804;0.1% frequency in liquid biopsy samples","Topics":null,"cSlideId":""},{"Abstract":"Background: Advances in artificial intelligence have paved the way for predicting cancer patients&#8217; survival and response to treatment from hematoxylin and eosin (H&#38;E)-stained tumor slides. Extant approaches do so either via prediction of actionable mutations and gene fusions, or directly from the H&#38;E images by training a task-specific model using large treatment outcome data.<br \/>Methods: Here we present the first approach for predicting patient response to multiple targeted treatments and immunotherapies directly from H&#38;E slides. It is founded on two conceptual steps: (1) First, we developed DeepPT, a deep-learning framework that trains on formalin-fixed, paraffin-embedded (FFPE) TCGA whole slide images and their corresponding gene expression profiles to predict wide-scale tumor gene expression from the slides. (2) Second, we apply ENLIGHT, a published approach that predicts individual responses to a wide range of targeted and immunotherapies based on the tumor biopsy measured transcriptomics. Here we apply ENLIGHT to predict patient treatment response from the DeepPT predicted expression values instead of those measured directly from the tumor, notably, without any further training or adaptation of ENLIGHT.<br \/>Results: First, we find that DeepPT generalizes well to predicting gene expression in all 13 TCGA cohorts tested in cross-validation and importantly, in two independent unseen breast and brain cancer datasets. DeepPT outperforms HE2RNA, a state-of-the-art algorithm for the same task. Second, we demonstrate that the combined DeepPT\/ENLIGHT pipeline (termed ENLIGHT-DeepPT) successfully predicts true responders using the original ENLIGHT decision threshold with odds ratios of 1.5 - 4.5, increasing the baseline response rates by 15-85% among predicted responders in five independent unseen cohorts of diverse cancer types and treatments. Remarkably, in one dataset where matched data was available, ENLIGHT-DeepPT has similar performance to that obtained by a supervised learning algorithm that was recently published in Nature, trained on the same cohort.<br \/>Conclusions: We present for the first time a general framework for predicting patient response to a broad array of targeted and checkpoint therapies from histopathological images, without reliance on treatment outcome data, which are yet scarce and challenging to obtain. Importantly, ENLIGHT-DeepPT offers clinicians real-time treatment recommendations when one cannot wait for sequencing results. Also, and due to its very low cost, we very much hope that it will facilitate the advent of precision oncology in developing countries.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++BCS02-02 Digital pathology ,,"},{"Key":"Keywords","Value":"Precision medicine,Deep learning,mRNA,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Danh-Tai Hoang<sup>1<\/sup>, <b>Gal Dinstag<\/b><sup>2<\/sup>, Leandro  C.  Hermida<sup>3<\/sup>, Doreen  S.  Ben-Zvi<sup>2<\/sup>, Efrat Elis<sup>2<\/sup>, Katherine Caley<sup>1<\/sup>, Sanju Sinha<sup>3<\/sup>, Neelam Sinha<sup>3<\/sup>, Christopher  H.  Dampier<sup>3<\/sup>, Tuvik Beker<sup>2<\/sup>, Kenneth Aldape<sup>3<\/sup>, Ranit Aharonov<sup>2<\/sup>, Eric  A.  Stone<sup>1<\/sup>, Eytan Ruppin<sup>3<\/sup><br><br\/><sup>1<\/sup>The Australian National University, Canberra, Australia,<sup>2<\/sup>Pangea Biomed, Tel Aviv, Israel,<sup>3<\/sup>National Cancer Institute, Bathesda, MD","CSlideId":"","ControlKey":"08977366-b918-46cc-bccd-d78328eee940","ControlNumber":"2628","DisclosureBlock":"&nbsp;<b>D. Hoang, <\/b> None.&nbsp;<br><b>G. Dinstag, <\/b> <br><b>Pangea Biomed<\/b> Employment, Stock Option.<br><b>L. C. Hermida, <\/b> None.&nbsp;<br><b>D. S. Ben-Zvi, <\/b> <br><b>Pangea Biomed<\/b> Employment, Stock Option. <br><b>E. Elis, <\/b> <br><b>Pangea Biomed<\/b> Employment, Stock Option.<br><b>K. Caley, <\/b> None..<br><b>S. Sinha, <\/b> None..<br><b>N. Sinha, <\/b> None..<br><b>C. H. Dampier, <\/b> None.&nbsp;<br><b>T. Beker, <\/b> <br><b>Pangea Biomed<\/b> Employment, Stock Option. <br><b>MedAware<\/b> Stock Option.<br><b>K. Aldape, <\/b> None.&nbsp;<br><b>R. Aharonov, <\/b> <br><b>Pangea Biomed<\/b> Employment, Stock Option.<br><b>E. A. Stone, <\/b> None.&nbsp;<br><b>E. Ruppin, <\/b> <br><b>Pangea Biomed<\/b> Unpaid consultant.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10216","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"28","PosterboardNumber":"30","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"4355","PresenterBiography":null,"PresenterDisplayName":"Gal Dinstag","PresenterKey":"a1196357-8c32-4cf6-9adc-ad5cc101f814","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"4355. Prediction of cancer treatment response from histopathology images for a broad set of treatments and indications","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"318","SessionOnDemand":"False","SessionTitle":"Biomarkers of Therapeutic Benefit 4","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Prediction of cancer treatment response from histopathology images for a broad set of treatments and indications","Topics":null,"cSlideId":""}]